



RESI REDEFINING
EARLY STAGE
INVESTMENTS


APRIL 11, 2016
HOUSTON, TX



Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to **Make a Compelling Connection**

ONSITE GUIDE





- Entrance
- Registration
- Investor Panels Track 1
- Investor Panels Track 2
- Workshops
- Food Stations
- Fire Exit
- RESI Innovators
- Exhibiting Companies
- Partnering Forum
- Partnering Check-In
- Ad-Hoc Meeting Area
- Refreshment Stations
- Restrooms



- Welcome to RESI @ TMCx - - - - - 2
- RESI Schedule - - - - - 3
- RESI Innovation Challenge - - - - - 5
- Exhibiting Companies - - - - - 13
- Investor Panels - - - - - 19
- Early Stage Workshops - - - - - 38
- Partnering Forum - - - - - 42
- Sponsors - - - - - 43
- Media Partners - - - - - 45

RESI

TMC | X

2016





Today, Life Science Nation has brought together hundreds of senior level executives from investment firms, corporate strategics, and emerging biotech, medtech and digital health companies to the TMCx accelerator space at the Texas Medical Center in Houston. We're delighted to welcome you all to Texas Medical Center's new innovation facilities. Today, TMCx will showcase their current class of digital health technologies, and JLABS will bring senior executives from Johnson & Johnson and a number of entrepreneurs from the JLABS incubators, including the new JLABS@TMCx that opened in March 2016.

The RESI Innovation Challenge features new technologies from here at TMCx's accelerator and beyond. Throughout the exhibit area, RESI Innovators are showcasing their technologies on poster displays. Inside your RESI badge you'll find five tokens of RESI Cash you can use to "invest" in the most promising of these technologies. Take the time to invest your RESI Cash wisely, and join us at the evening reception as we announce the winners!


RESI Partnering will provide another means for innovators and investors to come together, with investors represented from all of the categories of investors LSN tracks including Family offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. The RESI Partnering Forum will allow fundraising executives to identify and book up to 16 meetings with those diverse life science investors who fit their company's technology sector and stage of development. By using the RESI Partnering system to find fellow attendees based on fit, you can find meeting partners who align with your focus. With that match as a basis, RESI is a venue for compelling conversations between startups and investors in the life science space.

LSN would like to extend our thanks to the speakers who are participating in RESI's two Investor Panel tracks, and the presenters of the RESI Workshops. We're very glad that you're here to share your expertise with the entrepreneurs and investors who attend RESI. New topic areas include Healthcare System Partners and Connected Consumer Health, and at our 1pm session "The Future Is Now", representatives from TMCx, JLABS and Houston's forthcoming AT&T Foundry will speak about why Houston is now the place for healthcare innovation.

Thank you for joining us at this emerging hub of healthcare innovation. We hope to see you later this year in Toronto and in Boston. Until then, enjoy the show!

Sincerely,

Dennis Ford
Founder & CEO, Life Science Nation



RESI SCHEDULE

5:00 - 7:00 PM: Kickoff Reception

Johnson & Johnson INNOVATION | LABS
LABS • TMC

April 10

Track 1:
Investor
Panels

Track 2:
Investor
Panels

Track 3:
Entrepreneur
Workshops

Track 4:
Partnering
Forum

7:00 - 8:00 AM: Registration & Breakfast

April 11

8:00
-
8:50
AM

**BIOTECH
ANGELS**

**MEDTECH
ANGELS**

 **LIFE SCIENCE NATION**
Connecting Products, Services & Capital
**FUNDRAISING
BOOT CAMP**

9:00
-
9:50
AM

**CORPORATE VCS
& STRATEGIC
INVESTMENT**

**DIAGNOSTIC
INVESTORS**

 **HIREtech™**
R&D TAX CREDITS

**MORNING
EARLY STAGE
PARTNERING
FORUM**

10:00
-
10:50
AM

**BIG
PHARMA**

**MEDTECH
STRATEGICS**

 **VENTURE VALUATION**
GLOBAL VALUATION SERVICES
**HOW TO VALUE
YOUR STARTUP**

11:00
-
11:50
AM

**HEALTHCARE
SYSTEM
PARTNERS**

**MEDICAL DEVICE
INVESTORS**

**McDermott
Will & Emery**
CROWDFUNDING & REG A+

12:00 - 1:00 PM: Break for Lunch

(12:30 - 12:45 PM: Welcome to TMCx - Dr. Robbins, President & CEO, Texas Medical Center)

1:00
-
1:50
PM

**EARLY STAGE
THERAPEUTICS
INVESTORS**

THE FUTURE IS NOW
TMC | X 


**TALES FROM
THE ROAD**

2:00
-
2:50
PM

**FAMILY
OFFICES**

**HEALTHCARE IT
INVESTORS**

*Due to the popularity
of the panel sessions,
there is no workshop
scheduled to run during
this time slot.*

**AFTERNOON
EARLY STAGE
PARTNERING
FORUM**

3:00
-
3:50
PM

**VENTURE
PHILANTHROPY**

**INCUBATOR/
ACCELERATOR/
NEW MODELS**

 **BIC BOSTON
INNOVATION CAPITAL**

4:00
-
4:50
PM

**ASIA-PACIFIC
INVESTORS**

**CONNECTED
CONSUMER
HEALTH**

 **LIFE SCIENCE NATION**
Connecting Products, Services & Capital
**BRANDING &
MESSAGING**

5:00 - 7:00 PM: Cocktail Reception

TMC | X



RESI

REDEFINING
EARLY STAGE
INVESTMENTS

CONFERENCE SERIES

The **RESI Conference Series** offers fundraising CEOs an opportunity to meet early stage investors that are a fit for their sector four times every year. Use the discount code **RESISERIES** for **\$100** off of your RESI conference series registration.



HOUSTON, TX

APRIL 11, 2016

Johnson & Johnson INNOVATION
— JLABS —

TMC | X

LIFE SCIENCE NATION
Connecting Products, Services & Capital



TORONTO, ON

JUNE 23, 2016

Johnson & Johnson INNOVATION
— JLABS —



LIFE SCIENCE NATION
Connecting Products, Services & Capital



BOSTON, MA

SEPTEMBER 13, 2016

Johnson & Johnson INNOVATION
— JLABS —

LIFE SCIENCE NATION
Connecting Products, Services & Capital



SAN FRANCISCO, CA

JANUARY 10, 2017

LIFE SCIENCE NATION
Connecting Products, Services & Capital



We welcome you to participate in the RESI Innovation Challenge!




The RESI Innovation Challenge is a virtual investment contest, and the investor is you!

As you explore the exhibit hall, you will encounter 30 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will find five RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000.

- First Prize: Complimentary tickets to 3 RESI Conference Series events of your choice (2 tickets per event) and GoPro action camera sponsored by Medmarc
- Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event)
- Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets)



RESI Innovators



Easel 1



Easel 2



Easel 3



Easel 4



Easel 5



Easel 6



Easel 7



Easel 8



Easel 9



Easel 10



Easel 11



Easel 12



Easel 13



Easel 14



Easel 15



Easel 16



Easel 17



Easel 18



Easel 19



Easel 20



Easel 21



Easel 22



Easel 23



Easel 24



Easel 25



Easel 26



Easel 27




Easel 28



Easel 29



Easel 30



Molecular Assemblies is developing a next generation enzymatic DNA synthesis technology (writing genetic code) to replace the \$1.2B chemical process the founders developed and commercialized 30 years ago; now an impediment to modern application. The company has raised \$565k in SBIR grants, \$100k from friends and family and has recently closed a \$1.2M seed round. The first patent broadly covering composition of matter, method and apparatus for nucleic acids in general has recently been awarded in Europe and a second US patent was awarded in March 2016. The markets are big and growing. While hundreds of millions of dollars have been invested in circumventing the inherent problems of the old chemical process, only Molecular Assemblies is developing a completely next generation approach to enable a new era of biotechnology.



Beta Cat is a private cancer biotech company in Houston at JLABS and with a \$16MM CPRIT nondilutive award that triples private investment we raise up to \$8 MM during the next several years. We have small molecule inhibitors of key cancer stem cell pathways. Our lead program is in the WNT pathway where it drugs right before transcription, thereby providing the only highly potent and specific inhibitor of the pathway known today. This is a very important cancer target that has yet to be effectively drugged until our compound. We are currently in toxicological studies and plan for IND approval and clinical studies this year. The pathway has been shown to be a key resistance pathway that cancers utilize to develop resistance and work around chemotherapies, targeted therapies, and even the latest immune oncology therapies.



BioMarker Strategies has developed the recently patented SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers. Currently available biomarker tests for solid tumors are primarily based on dead fixed-tissue samples and do not accurately predict individual response. SnapPath® is unique in automating and standardizing functional profiling of live tumor cells from fresh, unfixed tissue samples – and makes possible a new class of biomarker tests that are highly predictive of individual response to treatment because they are based on dynamic and predictive signaling information available only from live cells.



Chrysalis BioTherapeutics, Inc. is a privately-held biopharmaceutical company developing peptide drugs to help eradicate brain tumors, regenerate neural stem cells, and restore cognitive function in the brain after radiation therapy. In children and adults with brain tumors, radiation therapy treatment damages neurons and neural stem cells resulting in memory loss and cognitive dysfunction that in children can last for their entire lives. The company's lead product, TP508, activates progenitor stem cells located within tissues to stimulate vascular and neural regeneration following radiation exposure and restore brain function. Chrysalis has utilized non-dilutive funding to complete proof-of-principle studies, met with the FDA, and is seeking funds to complete final IND enabling studies and initiate human clinical trials.



CureMeta is a Boston-based privately funded biotech company dedicated to developing novel immunology therapeutics for aggressive and metastatic cancers. Our approach to curing cancer is different. Our drug development strategy is driven by the hypothesis that metastatic and aggressive cancers are caused by "reprogramming" or "dedifferentiation" of a "stressed" cell backwards to a primitive, embryonic-like or pluripotent-like stem cell state. The CureMeta product engine has generated numerous antibodies highly specific to novel embryonic cancer targets. CureMeta's lead drug in our pipeline, Bstrongximab-ADC has strong and convincing preclinical data and the next step is clinical proof-of-concept in metastatic cancer patients.



Vax-Immune is focused on preventing and treating infections in pregnant women and babies through rapid diagnosis. More than 20% of pregnant women have infections which could lead to lung disease, developmental delay and death in babies. Our first product is a platform technology that miniaturizes incubation into a sample collection device. This enables the testing process to begin immediately and exponentially compresses the processing time, thereby enabling greater cost efficiencies, more accurate results and better outcomes for patients.



GeneSegues develops novel nanocapsule based solutions that can unlock the potential of promising drugs that need more precise delivery. Our technology is highly differentiated in that our ultra-small nanocapsule is 3x smaller than competing capsules and, due to their versatility and efficiency, can be readily designed to reach more targets with more drug leading to better treatment outcomes. We are using this technology to develop our own nanoencapsulated RNA drug for head and neck and colon cancers. In addition to developing our proprietary cancer drug candidate pipeline, we are seeking to partner our nanocapsules with drug developers in other cancer indications and other disease markets in need of innovative and effective targeted delivery solutions. We are actively engaged in a number of very high potential markets in need of new delivery technologies for RNAi, gene therapy and gene editing (also known as CRISPR). Because we can create new nanocapsules more quickly and significantly smaller than the competition, we can be a leader in some of the most exciting fields in medicine today.



Magellan Medical Systems is engaged in developing innovative technologies in mobile X-ray imaging for medical, veterinary and Non-Destructive Testing (NDT) applications. Our portable mini C-Arm X-ray imaging system is a novel and world first portable imaging and multiple function product entering into low cost and mobile diagnostic imaging and densitometry markets. Our technology has been awarded by two U.S. patents and two China patents. We will leverage the product's superior feature set and market timing to capture a significant market share, which historically rewards innovation with dominating market share. We anticipate U.S. FDA 510(K) clearance in 2016 and China FDA approval in 2017. Our revenue will begin in 2016 generated from sales in the veterinary markets.



PhotoniCare is fundamentally changing the way ear infections are managed by enabling physicians to look through the eardrum and into the middle ear. This results in better use of antibiotics and more appropriate surgical intervention. Our solution will improve patient outcomes, patient quality of life, reduce healthcare costs for this disease, and reduce the incidence of hearing loss, speech impairment, and learning disabilities in children. We've published several clinical studies on our technology and have well-defined regulatory and reimbursement strategies. We've raised \$2.5M to date and we are looking to raise \$5M in 2016 in order to launch our first product and expand our clinical trials.



MetriTrack's technology targets thousands of small, potentially curable breast cancers missed by mammograms in dense breasts or at follow up and the billions of dollars spent on unnecessary procedures and workflow inefficiencies in millions of breast ultrasound exams. Our proprietary software and sensor platform powers the BVN™ G-1000, first FDA cleared device designed to remove multiple user dependent, imprecise and inefficient tasks by providing automated, real time, precise mapping and processing of breast ultrasound images. BVN™ G-1000 integrates with the estimated global installed base of over 60,000 dedicated ultrasound units. The Company is at a pre-revenue stage, but already has its first product used in patients, positive feedback from key opinion leaders and a strong foundation of intellectual property.



Surgeons still suture or staple more than they'd like to, as medical glues don't live up to their requirements. Adhesys Medical seeks to change the game, developing one-of-its kind polyurethane-based surgical adhesives. The technology is unique as it combines ease of use, strength, flexibility and biodegradability, allowing for wound-closure on and in the body within seconds and use in unprecedented areas of surgery. Venture backed and based in the US and Germany, it is our vision to advance surgery by providing physicians with the tools to minimize complications and maximize patient comfort.



Saranas is developing a technology that will enable real time detection of internal bleeding complications associated with high risk vascular access procedures. Early detection of these complications will reduce additional healthcare costs, which will no longer be covered by insurance companies as of this year. The product has been designed to seamlessly integrate into the clinical workflow and will provide actionable alerts throughout the procedure. The underlying technology was exclusively licensed from the Texas Heart Institute and has been tested in over two dozen large animals to date. The company's patented technology allows for early detection of these complications and enables physicians to mitigate the downstream consequences by addressing the complication immediately.



Medical Informatics Corp has developed and commercially deployed a complete Clinical Intelligence Platform called Sickbay that is FDA-cleared for real-time, virtual patient monitoring and patient-centric analytics. Sickbay transforms patient data it into near real-time, web-based applications that are easy-to-use, intuitively designed, and fit into the clinical workflow. Apps are accessible through one web-based platform that can be turned on or off at any time for complete flexibility and scalability. Our team vision is to empower healthcare professionals to save lives by creating a paradigm shift in healthcare that transforms the way care is delivered and supports the delivery of a high performance health care system.



Thornhill Research Inc. is a privately held a spin-off company from the University Health Network in Toronto. We create and actualize unique devices that will bring new benefits to society, particularly in mitigating against disease and prolonging life. Our RespirAct™ device is an integral component in the development of a new "Brain Stress Test" (Cerebral Vascular Response or CVR) to identify patients at high risk of Stroke or Dementia. The need for a reliable, reproducible, non-invasive, low cost means of measuring CVR is well documented in the literature. Our technology has been validated by independent worldwide collaborators and over 1000 patients tested at the Toronto General Hospital.



Curtana Pharmaceuticals is an Austin-based preclinical-stage company focused on developing the first truly targeted small molecule therapeutics for the treatment of glioblastoma and other brain cancers. Curtana's lead candidate, CT-179, directly inhibits the transcription factor Olig2, which has been shown to be requisite for tumorigenesis. CT-179 is efficacious in a murine orthotopic PDX GBM model, is well tolerated at therapeutic doses, is nearly 100% orally bioavailable, readily crosses the blood-brain barrier, and achieves brain tissue concentration levels well above the IC99. The company is currently initiating IND-enabling studies and plans to be in the clinic early next year. To-date, Curtana has raised nearly \$9M, most of it as non-dilutive capital, with over \$5M still available to use.



DocResponse is a software platform focused on patient self-assessment that generates a differential diagnosis list with percentage likelihood, information about each diagnosis, and recommended next steps. It was built by board-certified specialist physician teams and covers over 300 diagnoses across seven specialties. DocResponse was found to be the most accurate technology of its kind in a Harvard Medical School peer-reviewed study (7/2015 BMJ), outperforming tech giants such as iTriage, WebMD, Mayo Clinic, and more. DocResponse is available for white-labeling/licensing (SaaS model) with integration via rest API. DocResponse decreases costs through decreasing unnecessary utilization, increases patient engagement, and increases revenues by increasing clinical efficiency and decreasing unnecessary specialist referrals. Target markets include payers, providers, and patients.



Aegle is developing a new platform of therapeutics based on its proprietary microvesicle isolation technology for the treatment of acute and chronic wounds and scarring. Our team has spent the past 25 years researching adult mesenchymal stem cells and successfully treating chronic wound and burn patients with these cells under multiple INDs. Our scientists discovered that stem cells continuously secrete microvesicles, which function as the critical mediators by which cells promote healing. Using microvesicles instead of cells for therapy is low cost and removes aberrant growth issues. Microvesicles secreted by mesenchymal stem cells and isolated by Aegle's method stimulated rapid healing, tissue regeneration and minimal scarring in validated porcine wound models. Aegle plans to file its first IND in 2016 for chronic pressure ulcers.



Will2Love offers online help for cancer-related problems with sexuality or fertility, issues affecting 60% of 14.5 million cancer survivors in the US (projected to grow by 31% by 2024). Interventions could also be easily tailored for other chronic illnesses or for sexuality and aging. Will2Love.com includes news, resources, webinars, and online moderated forums. Our evidence-based mHealth interventions for men and women can be supplemented with telehealth counseling by a nurse or psychologist. Development of our interventions was supported by three fast-track small business grants from the National Cancer Institute, with published outcome studies conducted at UT MD Anderson Cancer Center.



Valera Health harnesses each patient's unique health-relevant smartphone data to enable preventive rather than reactive behavioral healthcare, and engages patients with end-to-end services. Our approach leverages technology to scale proven models that achieve savings, improves outcomes and increases patient satisfaction. Our digital platform collects passive and active patient data, transforming it into actionable insights. We engage patients in targeted interventions before conditions worsen. We connect patients to care managers and behavioral health specialists using a validated cost-saving model for collaborative care. Our leadership has decades of healthcare experience: deploying integrated behavioral healthcare, and in healthcare policy, performance improvement, and financing.



GreenLight Medical is a cloud-based software to streamline the introduction, evaluation, and approval of new medical technology within hospitals. GreenLight is an end-to-end solution, offering a secure, collaborative, information-exchange platform to align medical device companies, medical sales representatives, hospital providers, and physicians in one all-inclusive tool. By eliciting coordination among multiple parties on new product evaluation, data, documents, and decisions can be analyzed from one shared space. GreenLight provides the actionable data and insights needed to enable medical suppliers and hospital providers alignment on cost, quality, and outcomes regarding new medical technology introduction.



Heart failure affects over 6 million Americans and is currently the single most expensive diagnosis in the US. Procyron, Inc. (Houston, TX) is developing aortix™, a cardiac assist pump thinner than a #2 pencil (6mm), implanted via catheter in an outpatient procedure. Aortix will be a first-in-class device, giving the cardiologist a new tool to treat chronic heart failure (a \$6-10B/year market opportunity) and improving patients' quality-of-life.



CareSet's software platform, Patch, leverages rich Medicare claims data to enable executives to evaluate their current provider networks and identify new opportunities for physician outreach, no integration necessary. Graph-based visualizations help teams quickly identify physicians driving large patient volume as well as those who split admissions among competing facilities. Patch performs custom provider-level searches based on affiliations, procedures, labs, medications, implied referral volumes, EMR/EHR attestations, and geographical patient distribution. The platform also supports strategic planning, and has helped executives evaluate markets in advance of risk-sharing contracts, M&A, and vertical integration.



CorInnova is developing a non-blood contacting biventricular cardiac assist device to treat end stage heart failure (HF) with the sponsorship of a premier international foundation. This technology could eliminate 40% of adverse events associated with left ventricular assist devices (LVADs), reducing healthcare costs and expanding the eligible patient population by 3 to 4 times. The resulting non-blood contacting heart failure device market could easily total \$3 - \$4 billion in the US, and \$2 - \$3 billion in Europe. Moreover, the device has the potential to promote cardiac restoration by correcting heart motion, a potential blockbuster application. Major medical device companies have expressed partnering interest after the upcoming first-in-human clinical trial, which is set to begin within 24 to 28 months. Other cardiac device companies with comparable markets have sold for up to \$450 million with only 10 patients' data.



Tech4Life offers a highly innovative web and mobile based telemedicine platform, called 'MDConsults', effectively used for online consultations in low bandwidth environments. Tech4Life has also launched its plug-n-play digital stethoscope (called eSteth) for better diagnosis during regular and telemedicine consultations, and portable non-invasive hemoglobin monitor, called Smart-Hb, for monitoring Anemia.



There is a great need for a new class of pain medications that can effectively reduce pain without the major side effects of existing pain medications. Most pain is localized but most analgesics are administered orally and work systemically. Opioids, while extremely effective in reducing pain, are accompanied by nausea, constipation, tolerance and risk of abuse. Non-steroidal anti-inflammatories have been associated with GI and cardiovascular disorders. Few locally delivered pain medications exist and even fewer are available in topical form. Formulated volatile anesthetics have tremendous potential to form a new class of topically applied analgesics to tackle localized pain, minimizing systemic side effects and reducing use of opioids and other systemically acting analgesics. Vapogenix is a clinical stage company developing a new class of pain medications based on formulations of volatile anesthetics (VAs) to treat a variety of localized painful conditions. VAs are currently unformulated and only approved for use by inhalation for general anesthesia. Vapogenix is formulating VAs into gels and liquids for topical delivery to treat localized pain. Vapogenix is currently developing 3 products: a rapidly acting topical analgesic to treat localized pain on intact skin, a topical medication to treat wound pain, and a topical analgesic for inflammatory pain.



Impel's Precision Olfactory Delivery (POD) device delivers aerosolized drugs to the upper nasal cavity where they are directly transported into the brain, bypassing the blood-brain barrier (BBB). The POD device enables biologic and small molecule drugs to effectively access the CNS that would otherwise be excluded by the BBB or metabolized in the plasma. Impel has a growing clinical pipeline of enhanced CNS drug products, including INP-101 (pain management, Phase 1), INP-102 (Alzheimer's, Phase 2) and INP-104 (migraine, Phase 2). Impel's pre-clinical pipeline includes the novel neuropeptides INP-105 (pain mgmt) and INP-106 (depression). Impel recently announced a strategic manufacturing and R&D alliance with 3M Drug Delivery Systems. Impel is currently raising a \$12M Series B round; 3M New Ventures lead a \$4M first-tranche that closed in Sept 2015.



MBio Diagnostics capitalizes on the trend towards providing instant answers through distributed testing and diagnostics. MBio's technology enables rapid, on-the-spot clinical diagnostics and sample testing. Our compact instrument and disposable cartridges provide multiple quantitative answers in just minutes. The MBio LightDeck® technology is scalable and proven through multiple evaluations. Recently MBio executed a partnership in food safety testing, and clinical development is underway. MBio will be the platform of choice for clinical and analytical applications in medical, veterinary, and food safety testing.



BeneSol presents the world's first photobiologic treatment enabling the safe, natural production of vitamin D. Vitamin D, along with other important hormones and peptides, is critical to systemic health. The members of BeneSol's management team are seasoned experts with track-records of successfully building and selling companies. BeneSol produces a month's supply of vitamin D in an average treatment of 2.5 minutes. Initial biologic testing demonstrates that we will provide the safest, most effective and natural production of vitamin D ever available. Our second stage will target multiple indications including immune system disorders. Rather than selling devices, BeneSol will charge per treatment creating a compounding recurring revenue stream. We intend to have a profound impact on human health, naturally and affordably.



AptamiR Therapeutics, Inc. is a biotechnology company founded in 2012, focused on developing a revolutionary treatment for human obesity. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (brown-like, brite or beige). MicroRNAs are attractive drug candidates for complex diseases like obesity, as they can modulate the expression of gene networks. AptamiR is also developing drug delivery approaches that can specifically target microRNA modulators to adipose tissue.



Agile Sciences is developing a more effective therapeutic strategy for treating multidrug resistant (MDR) bacterial infections. The company's core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial defense mechanisms through a novel mode of action resulting in enhanced antibiotic activity by inhibiting and dispersing bacterial communities, known as biofilms, and restoring antibiotic susceptibility in drug resistant infections. Agile Sciences' is targeting three therapeutic areas: 1) treatment of MDR bacterial infections; 2) treatment of lung infections in cystic fibrosis (CF) patients; and 3) treatment of chronic wound infections.



make the
CONNECTION

JLABS

JLABS, part of Johnson & Johnson Innovation, LLC, is a network of open innovation research centers providing emerging companies with many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so.

FIND OUT MORE ABOUT HOW YOU CAN JOIN US AT

[JLABS.jnjinnovation.com](https://www.jlabs.jnjinnovation.com)

WE WANT YOU!





THE BEST PLACE *on* EARTH *for* HEALTH START UPS

Inside access to more patients, physicians and hospitals than anywhere else in the world.



EXHIBITING COMPANIES

Exhibiting Companies

McDermott
Will & Emery

Table 1

TMC | X

Table 2

MEDMARC. Treated Early
COMBINED EXPERTISE + SUPERIOR PROTECTION™

Table 3

ALT
usedlabequipment.com

Table 4

PHARMATEK
PHARMACEUTICAL DEVELOPMENT & MANUFACTURING

Table 5

AdvaMed
2015 THE MEDTECH CONFERENCE
ACCESS. INSIGHT. OPPORTUNITY.

Table 6

Johnson & Johnson INNOVATION | JLABS
JLABS + TMC

Table 7

药明康德
WuXi AppTec

Table 8

ONTARIO
CANADA

Table 9

KINETA
innovation from within™
KPI™
THERAPEUTICS

Table 10

bionorthT
Changing lives through the convergence of science and biology.

Table 11

RECAPBIO:
TEXAS

Table 12

Atheln inc.
Propelling life science innovations

Table 13

MaRS

Table 14

HIREtech™

Table 15

Health
Breeze

Table 16

WG
THE WEATHERSBY
GROUP, INC.
LABORATORY CONSULTANTS

Table 17

W VENTURE VALUATION
GLOBAL VALUATION SERVICES

Table 18

bic
Boston Innovation Capital
Science & Technology Investments

Table 19

LIFE SCIENCE
NATION
Connecting Products, Services & Capital

Table 20



McDermott Will & Emery is a premier international law firm with a diversified business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 offices around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client's challenges.



Housed in 100,000 sq. ft. of a former Nabisco cookie factory, Texas Medical Center accelerator (TMCx) is a 6 month program that provides life science and digital health entrepreneurs with a collaborative ecosystem to accelerate their path to market. TMCx resources for startups include: an all-star network of advisors, a newly renovated office space, and unprecedented connections to the world's largest medical center. From ideation to commercialization, we work closely with life science and digital health startups to transform scientific innovations into tangible tools that save lives, manage disease, and improve quality of life.



Created in 1979 by the healthcare technology industry, Medmarc's purpose is to be the superior provider of liability insurance and related risk management solutions and to support the development, testing and delivery of products that save lives and improve the quality of life. Through our strategic alliances with The Hartford and clinical trial industry experts, we offer tailored insurance protection specifically designed for the broad spectrum of needs of the medical technology and life sciences industry. From ideas and prototypes to the reality of commercialization and success – We can Meet Your Changing Needs.



With more than 12,000 items spanning more than 100 categories of analytical instrumentation in stock, ALT is the largest provider of premium refurbished lab equipment in North America. Headquartered in East Lyme, Connecticut, west coast operations in San Diego, and sales offices in San Francisco, Raleigh, and Cambridge, ALT strives to provide the highest quality instruments at a very competitive price. Each item is carefully tested, serviced, and packed with care to ensure that it arrives safely in your lab. Add in a price match guarantee and up to a one year warranty, ALT is the most trusted source to outfit your entire lab. In 2015, ALT was recognized by Newsweek for its groundbreaking work with early stage life science companies through its ongoing sponsorships of high profile biotech incubators, LabCentral in Cambridge, MA and QB3@953 in San Francisco. Visit us at usedlabequipment.com.



Pharmatek is a contract development & manufacturing company providing dosage form development & cGMP manufacturing of oral, injectable & topical products. Founded in 1999, our services focus on the rapid advancement of small molecule & peptide drug candidates from the bench to the clinic. Our experience includes first-in-man strategies, solutions for poorly soluble compounds, controlled release formulations & separate facilities for the handling of cytotoxic & potent compounds. Pharmatek's 68,000 sq. ft. facility includes 9 class 100,000 cGMP manufacturing suites, formulation & analytical laboratories, & ICH stability storage. Pharmatek has over 150 clients globally, ranging from virtual to large pharmaceutical companies.



AdvaMed 2016 is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2016 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a "must-attend" event for any MedTech company. Whatever your goals may be, you are sure to accomplish, and even surpass them, at AdvaMed 2016.



JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.



WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to help its global partners in shortening the cycle and lowering the cost of R&D. WuXi is also building a platform to provide clinical diagnostic and genomic services directly to physicians and their patients globally.



The International Trade Branch assists Ontario companies in accessing international markets by establishing partnerships and distribution channels, and by providing assistance to foreign parties interested in sourcing Ontario products, technology and services. If you are an international buyer looking to source goods or services from Ontario, visit: SourceFromOntario.com.



Kineta®, Inc., founded in 2007 by Drs. Charles Magness and Shawn Iadonato, is a biotechnology company focused on the development of new and novel therapeutic drug candidates. We are currently focused on autoimmune, antiviral and pain. Our lead drug, dalazatide, is phase II ready. We have a progressive business model aimed at accelerating advancement of novel medicines to benefit patients and investors more quickly than traditional models. Kineta's corporate strategy is to discover novel compounds, advance them through Phase I of the development process and then partner with larger biopharmaceutical companies to conduct late stage development and commercialization.



KPI Therapeutics ("KPI") is a corporate development and funding consortium made up of Kineta, Inc. and several of its key strategic development partners. KPI's operating model uses an asset-centric model, where each drug candidate family is separately developed and commercialized with our development and commercialization partners.



BioNorth Texas is an independent, non-profit 501(c)(6) trade association serving and representing the life sciences industry in north Texas. BioNorthTX encourages the development of a rich ecosystem that allows for the growth and success of North Texas life science companies, as well as strengthening the economy of our local communities. We will do this through providing members support in capital formation; being the point of Information access and regional collaboration; through talent attraction and retention activities, by supporting national and state legislative activities and, by actively marketing the region as a vibrant location for life science business.



RecapBio: is a newsletter service that provides recaps of life science news and events, based on geographical divisions. It's our goal to grow to cover the latest developments from all of the world's top and emerging life science regions and clusters. RecapBio: also provides a look ahead with announcements and listings about upcoming events and conferences. Additionally, we have spotlight features and a growing social media network to help foster relationships and boost career growth. RecapBio: is anchored-sponsored by Johnson & Johnson, Innovation and The goal of its first edition, RecapBio:Texas, is to share the news and developments of this region in order to build a stronger, more connected community



Atheln is a product development and commercial team supporting companies and investors with their technologies in all phases of development and across all major classes of molecules and therapeutic areas. Our industry seasoned experts leverage their strategic and operational experience in start-up to large biopharma and medical device companies as well as with the FDA and payers to develop, validate, and manage product development and go-to-market strategies, plans, and activities for clients. Atheln integrates technical, regulatory, payer, market, and business needs to mitigate risk and maximize client success. Areas of expertise include non-clinical, CMC, quality, regulatory, project management, clinical, product and commercial strategies, business development/licensing, and market access/reimbursement.



MaRS

MaRS Discovery District (@MaRSDD) in Toronto is the one of the world's largest urban innovation hubs supporting a new generation of innovators who aim to make the world a better place by creating solutions in all technology areas spanning health, cleantech, financial and legal services, and e-commerce. It is a community that encourages entrepreneurial thinking through education programs and events, and helps startups launch, grow and scale. In the last three years, MaRS ventures have raised \$1.3 billion in capital and earned \$640 million in revenue. The MaRS Centre comprises 1.5 million square feet and is the home of notable life science organizations including: JLABS@Toronto, the Ontario Institute for Cancer Research, Synaptive Medical, and LEAGUE.



HIREtech™

HIREtech, is a technology focused human capital management solution and tax incentive firm helping companies capturing valuable tax credits. Exclusive technology enables companies to access real time data needed to make important decisions. HIREtech's solutions include hiring tax incentives, research and development tax incentive and other specialized tax incentive programs for companies of all sizes including startups. Bridging the gap between human resources and financial executives, HIREtech delivers innovation technology and award winning customer service.



Health
Breeze

Animated video is the most preferred media for effective medical communication. HealthBreeze is the world first "open medical animation studio" creating medical animations based on "Author-Publisher" model. If a group of healthcare professionals (Association, Institution, Teaching hospital, etc.) becomes HealthBreeze Author, HealthBreeze medical animation team creates high quality Animated Works based on the Author Content (Text based Patient Instruction, Brochure, Web document, etc.). The Animated Works will be opened through HealthBreeze Application, easily accessible for every healthcare professionals in the world. Other healthcare professionals and industries can also lease the animated video with affordable monthly payment model. Visit "<http://www.healthbreeze.com>" to meet our innovative open medical animation service.



VENTURE VALUATION
GLOBAL VALUATION SERVICES

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Venture Valuation offers independent company valuations for fund raising as well as product valuations for licensing deals.



Boston Innovation Capital
Smart & Modern Financing

Boston Innovation Capital (BIC), member SIPC / FINRA, is an advisory firm that was spun out of Life Science Nation (LSN) in 2014. BIC was founded in order to address an unmet need among early stage entrepreneurs in the biotech and medtech sectors for tactical, hands-on assistance in packaging technologies and management teams and executing fundraising campaigns. Scientist-entrepreneurs raising capital to bring their assets towards commercialization are faced with few choices when seeking outside help for fundraising. In the past, these choices would include small-scale investment banks, and retired bankers or industry executives who may or may not be associated with a broker-dealer. Most cannot provide the global reach and scale of service that allows an entrepreneur to find a clear and expeditious path to capital. Boston Innovation Capital was created to provide this global service, and to help new life science technologies take the next step towards the market.



LIFE SCIENCE
NATION
Connecting Products, Services & Capital

Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.

McDermott
Will & Emery

Raising the bar.

McDermott Will & Emery's Life Sciences Entrepreneurs Acceleration Program (LEAP) helps emerging companies avoid costly mistakes and chart their courses for success. We provide strategic legal advice at crucial foundational stages of a company's life using a variety of flexible and deferred fee arrangements. Learn more at www.mwe.com/leap/.

Please join our session "New Sources of Capital for your Life Science Company," focused on Crowdfunding and Reg A+, at 11:00 am (Track3).

www.mwe.com



McDermott Will & Emery conducts its practice through separate legal entities in each of the countries where it has offices. This communication may be considered attorney advertising. Previous results are not a guarantee of future outcome.

HIREtech™

- + Research & Development Tax Credit
- + Start-Up Tax Credit
- + Grant Screening & Writing

hiretech.com
844.HIREtec

Global Platform. One Vision.

WuXi AppTec is a global leader in providing discovery, testing, and manufacturing services to the biopharmaceutical and medical device industries. With strong operations in the U.S. and China, WuXi AppTec offers a comprehensive portfolio of services to assist our customers with highly cost-effective solutions.

www.wuxiapptec.com



Passion



Integrity



Expertise



Small Molecules



Biologics



Cell Therapies



Medical Devices



Genomics

SHANGHAI ST. PAUL SUZHOU ATLANTA WUHAN PHILADELPHIA TIANJIN SAN DIEGO
CHANGZHOU TEL AVIV PLAINSBORO WUXI BOSTON SEOUL REYKJAVIK JINSHAN

COMBINED EXPERTISE SUPERIOR PROTECTION

FOR MEDICAL TECHNOLOGY AND LIFE SCIENCES COMPANIES



For more information or to subscribe to our newsletter visit Medmarc.com/News or email us medtechlifesci@medmarc.com

WHAT NUMBERS ARE NEEDED FOR A BUSINESS PLAN?

- Insurance coverages and cost typically needed to start a business
- Clinical trial insurance pricing and requirements in and outside of the United States

Find out, call George Ayd at 703-652-1309 or email gayd@medmarc.com

We are an alliance of insurance specialists, each with a deep understanding of the medical technology and life sciences environments, each well versed in the specific challenges you face. Our combined expertise is unmatched in the industry and translates into comprehensive coverage and risk management solutions which help you protect your balance sheet and control insurance costs.



Track 1	Moderator & Panelists
<p>8:00 - 8:50 AM</p> <p>BIOTECH ANGELS</p>	<ul style="list-style-type: none"> • Luke Fouke, Co-Founder & CEO, <i>American Research Capital</i> • Bril Flint, Board Member, <i>Central Texas Angel Network</i> • Russell Allen, Co-Founder & Managing Director, <i>Bio/Med Investor Network</i> • Stefan Weiss, Angel Investor, <i>New World Angels</i> • Anudeep Jain, Angel Investor, <i>Pathfinder Enterprises</i>
<p>9:00 - 9:50 AM</p> <p>CORPORATE VCS & STRATEGIC INVESTMENT</p>	<ul style="list-style-type: none"> • Elona Baum, Managing Director, <i>DEFTA Partners</i> • Henry Skinner, Managing Director, <i>Novartis Venture Funds</i> • Martin Heidecker, Managing Director, <i>Boehringer Ingelheim Venture Fund</i> • Vinzenz Ploerer, President & CEO, <i>Brace Pharma Capital</i>
<p>10:00 - 10:50 AM</p> <p>BIG PHARMA</p>	<ul style="list-style-type: none"> • William Kohlbrenner, Chief Scientific Officer, <i>Life Science Nation</i> • Barbara Araneo, External Innovation Sourcing Director, <i>Novo Nordisk</i> • Joseph Simeone, Director, Enabling Technologies, Search & Evaluation Lead, <i>Merck</i> • Marc Schwabish, US Head, Pharma Business Development & Licensing, <i>Bayer</i> • Mark Day, Executive Director & Head of External Research and Scouting, <i>Alexion Pharmaceuticals</i>
<p>11:00 - 11:50 AM</p> <p>HEALTHCARE SYSTEM PARTNERS</p>	<ul style="list-style-type: none"> • Rebecca Kaul, President & Chief Innovation Officer, <i>MD Anderson Cancer Center</i> • Cheng-Kai Kao, Medical Director of Informatics, <i>University of Chicago Medical Center</i> • James Hury, Director, Finance, <i>Texas Children's Hospital</i> • Sharmila Anandasabapathy, Vice President, Global Initiatives, <i>Baylor College of Medicine</i>
<p>1:00 - 1:50 PM</p> <p>EARLY STAGE THERAPEUTICS INVESTORS</p>	<ul style="list-style-type: none"> • Lisa Rhoads, Managing Director, <i>Easton Capital</i> • Atul Varadhachary, Managing Partner, <i>Fannin Innovation Studio</i> • Thorsten Melcher, Senior Director, New Ventures & Partnerships, <i>Johnson & Johnson Innovation</i> • John Westwick, Entrepreneur in Residence, <i>Mercury Fund</i> • Michael Lang, Chief Product Development Officer, <i>Cancer Prevention and Research Institute of Texas</i>
<p>2:00 - 2:50 PM</p> <p>FAMILY OFFICES</p>	<ul style="list-style-type: none"> • Colin Widen, CEO, <i>Boston Innovation Capital</i> • Jayson Rieger, SVP of Business Development & Portfolio Management, <i>PBM Capital</i> • Julia Belaya, Corporate Partnerships, <i>Plug and Play</i> • Robert Hatcher, President & CEO, <i>Cockrell Interests</i> • Sean Kearney, Managing Director, <i>Three Leaf Ventures</i>
<p>3:00 - 3:50 PM</p> <p>VENTURE PHILANTHROPY</p>	<ul style="list-style-type: none"> • Jit Patel, VP of Research & Business Development, <i>Juvenile Diabetes Research Foundation</i> • Debra Miller, Founder & CEO, <i>CureDuchenne</i> • Grace Pavlath, Senior Vice President & Scientific Program Director, <i>Muscular Dystrophy Association</i> • John Parker, Trustee, Managing Director (CH Innovations), <i>Charles H. Hood Foundation</i> • Rick Jones, Director, <i>Broadview Ventures</i>
<p>4:00 - 4:50 PM</p> <p>ASIA-PACIFIC INVESTORS</p>	<ul style="list-style-type: none"> • Richard Soll, SVP, International Discovery Service Unit, <i>WuXi AppTec</i> • Jun Lu, VP & Managing Partner, <i>Vesalius Ventures</i> • Lu Zhang, Managing Partner, <i>NewGen Venture Partners</i> • Masashi Kiyomine, Investment Director, <i>Mitsui Global Investment</i> • Yuwen Liu, Founding Partner, <i>BOHE Angel Fund</i>



RESI

REDEFINING
EARLY STAGE
INVESTMENTS

CONFERENCE SERIES

The **RESI Conference Series** offers fundraising CEOs an opportunity to meet early stage investors that are a fit for their sector four times every year. Use the discount code **RESISERIES** for **\$100** off of your RESI conference series registration.



HOUSTON, TX
APRIL 11, 2016

Johnson & Johnson INNOVATION
— JLABS —

TMC | X

LIFE SCIENCE
NATION
Connecting Products, Services & Capital



TORONTO, ON
JUNE 23, 2016

Johnson & Johnson INNOVATION
— JLABS —



LIFE SCIENCE
NATION
Connecting Products, Services & Capital



BOSTON, MA
SEPTEMBER 13, 2016

Johnson & Johnson INNOVATION
— JLABS —

LIFE SCIENCE
NATION
Connecting Products, Services & Capital



SAN FRANCISCO, CA
JANUARY 10, 2017

LIFE SCIENCE
NATION
Connecting Products, Services & Capital



Track 2 Moderator & Panelists	
<p>8:00 - 8:50 AM</p> <p>MEDTECH ANGELS</p>	<ul style="list-style-type: none"> • Robert Tucci, Managing Director, <i>Texas Halo Fund</i>  • David Franklin, Co-Founder, Managing Director, <i>Houston Health Ventures</i> • Chuck McCoy, Founder & Executive Director, <i>North Texas Angel Network</i> • Ky Calder, Board Member, <i>WINGS - The Washington Medical Technology Angel Network</i> • Alan Glowczwski, Member, <i>Aggie Angel Network</i>
<p>9:00 - 9:50 AM</p> <p>DIAGNOSTIC INVESTORS</p>	<ul style="list-style-type: none"> • John Walter, Chief Executive Officer & President, <i>Alliance for Cancer Gene Therapy</i>  • Caroline Popper, President, <i>BCM Technologies</i> • Tom Hawes, Managing Director, <i>Sandbox Industries</i> • Tom Miller, Managing Partner, <i>GreyBird Ventures</i> • Wouter Meuleman, Director of Corporate Development, <i>Illumina</i>
<p>10:00 - 10:50 AM</p> <p>MEDTECH STRATEGICS</p>	<ul style="list-style-type: none"> • Patrick Brennan, Director of Business Development, <i>Life Sciences Conference Group</i>  • Bill Waller, Lead Counsel, <i>Varian Medical Systems</i> • Sherrie Perkins, Vice President, <i>Sleep Apnea (New Ventures), LivaNova</i> • Nicholas Mourlas, Sr. Director New Ventures, <i>Johnson & Johnson Innovation</i> • Suzanne Hagin, Sr. Marketing Projects Developer, <i>Air Liquide Healthcare</i>
<p>11:00 - 11:50 AM</p> <p>MEDICAL DEVICE INVESTORS</p>	<ul style="list-style-type: none"> • Angela Shah, Editor, <i>Xconomy</i>  • Andrew Offer, CFO & Managing Director, <i>Scientific Health Development</i> • James Eadie, Partner, <i>Santé Ventures</i> • Philip Sanger, Managing Partner, <i>Texo Ventures</i> • Steve Banks, Venture Partner Emeritus, <i>S3 Ventures</i>
<p>1:00 - 1:50 PM</p> <p>THE FUTURE IS NOW</p> <p>TMC X AT&T FOUNDRY <small>JOHNSON & JOHNSON INNOVATION ILLUMINA SLAB</small> <small>KLARIS - TMC</small></p>	<ul style="list-style-type: none"> • Nicole Fisher, Founder & CEO, <i>HHR Strategies</i>  • Erik Halvorsen, Director, <i>Innovation Institute at Texas Medical Center</i> • Judi Manis, RVP of Strategic Relations & BD, <i>Internet of Things Healthcare, AT&T Foundry</i> • Lesley Stolz, Senior Director of Transactions, <i>Johnson & Johnson Innovation</i>
<p>2:00 - 2:50 PM</p> <p>HEALTHCARE IT INVESTORS</p>	<ul style="list-style-type: none"> • Joe Cunningham, Managing Director, <i>Santé Ventures</i>  • Aaron Nelson, General Partner, <i>dRx Capital</i> • David Orlandella, Managing Director, <i>ORIX Ventures</i> • Dennis Depenbusch, Director, <i>New Ventures Initiative, Blue Cross and Blue Shield of Kansas</i> • Ulili Onovakpuri, Venture Partner, <i>Fresco Capital</i>
<p>3:00 - 3:50 PM</p> <p>INCUBATOR/ACCELERATOR/NEW MODELS</p>	<ul style="list-style-type: none"> • Leo Linbeck III, Chairman & Founder, <i>Fannin Innovation Studio</i>  • Blair Kessler, Manager, <i>Healthbox</i> • David Huizenga, Co-Founder, President & CEO, <i>TAO Life Sciences</i> • Dianne Carmichael, Managing Director, <i>MaRS Discovery District</i> • Hubert Zajicek, CEO & Co-founder, <i>Health Wildcatters</i>
<p>4:00 - 4:50 PM</p> <p>CONNECTED CONSUMER HEALTH</p>	<ul style="list-style-type: none"> • Steve Welch, Founder, <i>DreamIt Ventures</i>  • Sean Kearney, Managing Director, <i>Three Leaf Ventures</i> • Marcia Dawood, Managing Partner, <i>BlueTree Allied Angels</i> • Stefanie Dhanda, Senior Director of Consumer Scientific Innovation, <i>Johnson & Johnson Innovation</i> • Huan Le, Co-Founder, Managing Director, <i>Houston Health Ventures</i>



• **Luke Fouke**, Co-Founder & CEO, *American Research Capital* 

Luke Fouke is the Co-Founder of American Research Capital LLC and currently serves as CEO. American Research Capital provides structured debt financing to small businesses performing research under federally sponsored research contracts. Previously Luke spent five years raising capital for Kineta Inc., a small biopharmaceutical company in the Seattle area, primarily through Angel investors. Prior to Kineta, Luke worked as a commercial banker at Southwest Bank of St. Louis, as a Senior Equity Analyst for Friedman Billings Ramsey in Washington DC and Delafield Hambrecht in Seattle. He holds a BA in History and Spanish from Denison University and a MBA from The Olin School of Business at Washington University.



• **Brill Flint**, Board Member, *Central Texas Angel Network*

Brill is Chairman-Emeritus and a current Board Director of the Central Texas Angel Network (CTAN), based in Austin, Texas. CTAN is one of the most active angel groups in the country, with over 130 members and a portfolio of well over 100 funded companies. Brill is one of the more active CTAN members, investing in MedTech, BioTech, consumer, B2B, software, mobile and other industries. Brill is currently the Chief Product Technology & Supply Chain Officer of Neogenis Labs, an early stage biotech company that has licensed IP from the University of Texas Health Science Center in Houston. Neogenis has been bootstrapped with minimal startup capital, and completed 2014 with almost \$14 million in revenue. Brill is an experienced Technology and Media Executive, with skills in Strategic Planning, Analysis, M&A, Operations and Finance. Brill's management career began at Bain & Co., where he was a Consultant and Engagement Manager. After Bain, Brill worked in the recorded music business. He was Vice President of Strategic Planning for the North American division of EMI-Capitol Music in the mid-90s, its most profitable period ever. Following EMI, Brill built and organized the Corporate Planning department at Dell Computer, helping the company grow from \$7B in revenue to \$30B. He was also VP of Planning and Finance for Worldwide Operations at Dell, including manufacturing, distribution, and procurement. In addition, Brill was the VP of Planning and Finance for the Large Corporate Accounts sales group at Dell.



• **Russell Allen**, Co-Founder & Managing Director, *Bio/Med Investor Network*

Russell Allen is co-founder and managing director of the Bio/Med Investor Network, an angel network focused on biotech, pharma, devices and digital health. Allen is also the president and CEO of Georgia Bio, where he directs programs and initiatives that contribute to the positioning of Georgia as a bioscience leader. Major responsibilities include business development and issue management related to capital formation, workforce development, education and commercialization. Previously, Allen was President and CEO of BioFlorida, and led one of the nation's largest industry growth periods from 2006 to 2013. Prior to BioFlorida, Allen led BioSouth, an organization that supports commercialization, licensing and partnering efforts for the bioscience industry throughout the southern U.S. In 1996 Allen co-founded Newton Park, a successful marketing, development and interactive strategy firm, and he led the organization from start-up to one of the top five digital marketing agencies in Atlanta. In 2001, Russell founded BioQuotient, a bioscience consulting and marketing firm before becoming a VP of biosciences at the Metro Atlanta Chamber of Commerce. Allen received a bachelor's degree in biology from Pepperdine University and a certificate in Biotech Enterprise Management from the Owen Graduate School of Business at Vanderbilt University. Currently, he serves on the board of directors for Georgia Bio, Bio/Med Investor Network, Georgia Life Sciences Coalition, Council of State Bioscience Associations and Southeast BIO.



• **Stefan Weiss**, Angel Investor, *New World Angels*

Stefan C Weiss, MD MBA is an Investor and Medical Entrepreneur. Currently, he is the CEO of Aniluxx Biotechnology, a biopharmaceutical start-up focused on addressing unmet needs in veterinary dermatology and the Managing Partner of Synchronous Health, a consultancy focused on accelerating early stage ventures in biopharmaceuticals and digital health and advising acquirers on the commercial potential of innovations in those verticals. Previously, Dr. Weiss was Senior Medical Director at Connetics Corporation, through its acquisition by Stiefel/ GlaxoSmithKline. During his tenure, he advanced successfully three drug candidates through NDA approval. Dr. Weiss graduated with his BA from Yale University, his MD and MHS from Duke University, his MBA from the Kellogg School of Management, and completed residency training in Dermatology at Stanford University Medical Center and a fellowship at the National Institutes of Health.



• **Anudeep Jain**, Angel Investor, *Pathfinder Enterprises*

Dr. Jain is a graduate of Rice University with a bachelor's degree in biochemistry. He then attended the University of Texas Medical School at Houston, graduating with Honors and a member of Alpha Omega Alpha Honor Medical Society. After medical school, he completed a residency in Diagnostic Radiology at the University of Cincinnati, followed by a one year sub-specialty radiology fellowship in Body Imaging (CT/Ultrasound/MRI). He was in private practice in a large radiology group in Houston, Texas for 20 years. A few years ago, he started his own radiology consulting practice and simultaneously began privately investing in early stage life science start ups, primarily with the support and guidance of Fannin Innovation Studios.



• **Elona Baum**, Managing Director, *DEFTA Partners* 

Elona Baum is Managing Director of DEFTA Partners and has 20 years of biotech and regenerative medicine management experience. Prior to joining DEFTA Partners, Ms. Baum served as a senior executive (General Counsel & VP Business Development) for five years at the California Institute for Regenerative Medicine ("CIRM"). During her tenure, CIRM invested nearly \$1 billion in regenerative medicine programs, created a \$40 million iPSC bank and launched annual roundtable meetings with FDA. Prior to joining CIRM, Ms. Baum held senior positions in the legal and regulatory departments at Genentech Inc. for over a 13-year span. Ms. Baum received her BA in Economics from the University of California (Cum Laude) and her JD from the University of San Francisco School of Law (Magna Cum Laude). She served as an extern for Justice John A. Arguelles, California Supreme Court. Ms. Baum is a frequent speaker at industry conferences and is an active mentor with Enterprise Futures Network.

• **Henry Skinner**, Managing Director, *Novartis Venture Funds*



Dr. Henry Skinner is a Managing Director in Cambridge, MA, USA. Prior to joining NVF, he worked as Executive Director & Global Head Strategic Alliances at the Novartis Institutes for Biomedical Research where he led a team responsible for identification, negotiation and management of collaborations and licenses for Novartis' therapeutic technology areas. Prior to joining Novartis he was CEO of SelectX Pharmaceuticals and President and CEO of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was Director of Technology Acquisitions for Pharmacia & Upjohn and managed business development and licensing for research platforms and therapeutic areas worldwide. Prior to Pharmacia, he was Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at Baylor College of Medicine and earned his PhD in Microbiology and MS in Biochemistry from the University of Illinois. Henry serves on the boards of Aeglea, AMP Therapeutics, Galera, Macrolide Pharmaceuticals, Proteostasis and Quartet Medicine.

• **Martin Heidecker**, Managing Director, *Boehringer Ingelheim Venture Fund*



Martin is Managing Director of Boehringer Ingelheim Venture Fund USA, Inc. Martin joined the Boehringer Ingelheim Venture Fund (BIVF) in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. He serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas, CA, 121bio in Cambridge, MA and Sentien Biotech, in Medford, MA. Martin holds Master degrees in Biology and Economy and received his doctorate from University of Wuerzburg, Germany.

• **Vinzenz Ploerer**, President & CEO, *Brace Pharma Capital*



Vinzenz Ploerer is Brace Pharma Capital's President and CEO, and sits on the Board of Directors. Vinzenz has worked as a life science executive for over 20 years, and brings extensive leadership experience in operations, acquisitions and business development. Prior to launching Brace in 2013, he worked at EMS S/A as Senior Vice President of Strategy and Operations. He has also held multiple senior leadership positions at Novartis/Sandoz including various country head roles. Vinzenz currently sits on several corporate boards including GeNO, Therabron, Tyrogenex and Navitor. Vinzenz obtained his Masters of Business Administration from the University of Innsbruck.



• **William Kohlbrenner**, Chief Scientific Officer, *Life Science Nation* 

Dr. Kohlbrenner is currently Chief Scientific Officer at Life Science Nation (LSN), a Boston-based company that provides a uniquely differentiated suite of services for emerging life science companies. Prior to joining LSN in 2014, Dr. Kohlbrenner was a director at AbbVie (Abbott pharma) where he was involved in identifying and pursuing external research opportunities and early-stage assets around the globe. This work included leading a global scouting team and conducting strategic assessments of early- and late-stage pipeline opportunities in multiple therapeutic areas. Earlier in his career, Bill led drug discovery research programs in several areas, including oncology, antivirals and antibacterials.



• **Barbara Araneo**, External Innovation Sourcing Director, *Novo Nordisk*

Barbara Araneo, Ph.D., serves Novo Nordisk, Inc as a Director in External Innovation Sourcing, a unit linked to Novo Nordisk's Global Research Department. Previously, she was a member of the JDRF Research team as the Director of the Diabetes Complications Therapeutic Area, where her role was to create and manage a portfolio of externally funded research grants aimed at translation of primary discovery along the path of new therapeutics and biomarkers. Dr. Araneo served on the faculty of the University of Utah's Department of Pathology as Associate Professor and has over 70 publications and 30 patents. In addition to her academic career, Dr. Araneo was Vice President of Development at StemCells Inc., where she was responsible for directing the effort to bring the company's neural cell-based product candidate from the exploratory and preclinical proof of principle stages into clinical development under the FDA regulatory process. Over her career Dr. Araneo specialized in translational research concentrating on bringing disease-modifying targets through validation and drug proof of concept. She has led project teams to enable filing of INDs, communicate with the FDA and initiate first in man clinical trials.



• **Joseph Simeone**, Director, Enabling Technologies, Search & Evaluation Lead, *Merck*

Joe is currently a Director within the Enabling Technologies group of Merck Research Labs Business Development and Licensing department. His current focus is on the search and evaluation of technologies for drug delivery/formulations and all aspects of biologics discovery and development. Prior to the S&E role, Joe was responsible for transacting discovery focused business deals in support of several therapeutic areas. Joe joined Merck in 1993 as a chemist and over his seventeen-year career in the laboratory he has held several positions of increasing responsibility within the discovery and pre-clinical organizations. Joe received his Ph.D. in Organic Chemistry from Seton Hall University studying applications and mechanisms of palladium-catalyzed cross-coupling reactions.



• **Marc Schwabish**, US Head, Pharma Business Development & Licensing, *Bayer*

Marc Schwabish, Ph.D., currently heads US Pharma Business Development & Licensing at Bayer. He works across Bayer's therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Dr. Schwabish had both Business Development and Alliance Management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets – from early research technologies through commercialized therapeutics. Dr. Schwabish previously worked in Healthcare Investment Banking (Leverage Finance and M&A), Pharma Strategy Consulting, and other Pharma/Biotech Companies (R&D and Product Management). He holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.



• **Mark Day**, Executive Director & Head of External Research and Scouting, *Alexion Pharmaceuticals*

Mark's background and experience spans across various leadership roles in Business Development (M&A), Academic Science, Drug Discovery & Translational Medicine. Currently he heads a new department at Alexion Pharmaceuticals, External Research and Scouting, and is an Adjunct Assistant Professor at Yale University. In his previous position at BMS, he was responsible for the search and evaluation of iPierian Inc, and together with key stakeholders at BMS, championed the acquisition of the company, which closed on April 29th 2014. He has published over 60 peer-reviewed manuscripts in leading journals including Nature & Science.

HEALTHCARE SYSTEM PARTNERS




TRACK 1



• **Rebecca Kaul**, President & Chief Innovation Officer, *MD Anderson Cancer Center* 

Rebecca Kaul is Vice President and Chief Innovation Officer of MD Anderson Cancer Center, the world's premier cancer center. She works closely with their Information Services, Hospital and Clinical Operations, Strategic Industry Ventures, faculty and leadership to identify creative and effective approaches for delivering the best possible patient outcomes and bringing these solutions to market. Previously, Rebecca served as Chief Innovation Officer and President of the University of Pittsburgh Medical Center's Technology Development Center where she built the Innovation Center from the ground up to a level of national recognition and developed a portfolio of partnerships, investments and new companies.




• **Cheng-Kai Kao**, Medical Director of Informatics, *University of Chicago Medical Center*

Cheng-Kai Kao, MD, is an academic hospitalist who is board certified in clinical informatics. His areas of interests include clinical decision support, population health management, mobile health, and international patient care. Dr. Kao currently serves as medical director of informatics, and his work focuses on leveraging technology to enhance clinical workflow, developing clinical decision support tools, and making innovations to improve care quality and patient experience. Dr. Kao is the chair of the clinical process review committee, where he leads an interdisciplinary team with delegated responsibility for review and approval of inpatient decision making processes. He also teaches courses of clinical informatics at both University of Chicago Pritzker School of Medicine and the new master program in biomedical informatics. Additionally, Dr. Kao also serves as medical director of international patient services, and oversees the clinical course of international patients from all over the world, optimizes their care quality and experience, and fosters global collaboration with overseas academic medical centers and healthcare organizations.



• **James Hury**, Director, Finance, *Texas Children's Hospital*

James Hury leads Commercialization and partners with TCH IS to co-lead Telemedicine at Texas Children's Hospital. In this role, James assesses and supports business lines and technologies that support Texas Children's mission. James's experiences range from leading a commercialization program including proof of concept and new company start up, developing telehealth capabilities for pediatric population management, developing and executing strategic initiatives, and improving the performance of existing product lines. His primary focus is emerging business opportunities. Prior to joining Texas Children's, James was the VP of Operations and Finance for a large Radiology practice and President of a wholly owned billing company. James gained his foundation for healthcare management from the Jones School of Management at Rice University MBA program and currently teaches a Ventures Lab at the Jones School.



• **Sharmila Anandasabapathy**, Vice President, Global Initiatives, *Baylor College of Medicine*

Sharmila Anandasabapathy, M.D. is a Professor of Medicine in Gastroenterology and Vice President, Baylor Global Initiatives and the Baylor Global Innovation Center at Baylor College of Medicine, Houston, Texas. In her current role, she oversees Baylor's global programs and affiliations. The Baylor Global Innovation Center seeks to develop novel, environmentally appropriate technologies and approaches to addressing global disease burden. This includes the development and validation of innovative mobile-applications for clinical care, point-of care diagnostic technologies, and portable, low-cost devices for the diagnosis and management of chronic, non-communicable diseases worldwide. An advanced gastrointestinal endoscopist by training, Dr. Anandasabapathy's research focus involves the development and validation of novel technologies for diagnosis of early gastrointestinal cancer. In addition to her primary appointment at Baylor, Dr. Anandasabapathy also holds an adjunct appointment in Bioengineering at Rice University in Houston, Texas. She holds a B.A. in English literature from Yale University and an M.D. from the Albert Einstein College of Medicine. She completed her Internal Medicine Training at the New York Hospital-Cornell Medical Center and Memorial Sloan Kettering Cancer Center and her gastroenterology fellowship at The Mount Sinai Medical Center, NY.

EARLY STAGE THERAPEUTICS INVESTORS

TRACK 1



• **Lisa Rhoads**, Managing Director, *Easton Capital* 

Lisa joined Easton Capital in 2010 when she repatriated from Bermuda. Lisa was previously with Celtic Pharma, a Bermuda-based global biotech private equity firm where she was a founding member of the management team. Lisa's spent the last 7 years acquiring and developing a portfolio of later-stage biotech programs where she was involved with all aspects of the development process and managed Intellectual Property portfolio. Lisa has been involved in all aspects of the investment and development process and sits on the board of electroCore, PerceptiMed, Shimojani, and observer board role for Resolve. Lisa also sits on the board at America's Best Home Healthcare, a home healthcare company. Prior to her role with Celtic Pharma, Lisa consulted and helped launched a number of Hedge Funds and has held senior positions in the Pharma industry with Bristol Myers Squibb J&J's McNeil Consumer Products Company and Zeneca's US pharmaceutical division.



• **Atul Varadhachary**, Managing Partner, *Fannin Innovation Studio*

Atul is Managing Partner at Fannin Innovation Studio which works with innovators at the institutions in the Texas Medical Center in Houston to help commercialize early-stage technologies in the life sciences. Fannin partners with innovators to co-found companies that it actively manages in addition to putting in seed capital and providing space. Atul is a physician with a PhD in Physiology from Johns Hopkins, and over two decades of experience in life sciences and healthcare. Before Fannin, Atul served as President of U.S. Operations at Reliance Life Sciences, part of the Reliance Group, India's largest private sector enterprise with over \$75 billion in annual revenues. Atul served for nine years as President & COO of Agennix, Inc., a late-stage biotechnology company where he led advancement of Agennix's lead molecule from preclinical studies into pivotal Phase 3 human studies and helped lead a successful sale of the company. Atul also served as Senior Engagement Manager at McKinsey & Co. Atul has served on the faculties of Baylor College of Medicine, Rice Graduate School of Management, and the UT School of Public Health. He has served on multiple company and community boards including that of the Harris Health System Board, and is on the Healthcare Advisory Committee of the Greater Houston Partnership.



• **John Westwick**, Entrepreneur in Residence, *Mercury Fund*

John K. Westwick, Ph.D. is CEO of Resonant Therapeutics, Inc, a biotech start-up creating breakthrough therapies for cancer treatment. He is also Entrepreneur-In-Residence, Life Sciences with Mercury Fund, where he is actively seeking out new oncology therapies and technologies. John has worked in research and drug discovery for over 32 years. Prior to Resonant, he was CEO of Odyssey Thera, a biotechnology company that developed breakthrough technologies for cell systems biology and established multi-year alliances with Pfizer, Merck and Co., Abbot Pharmaceuticals, ThermoFisher, and the US EPA among others. Dr. Westwick has contributed to multiple drug development programs that are marketed or in development, and has published more than 60 scientific articles and patents. Dr. Westwick previously held scientific leadership positions at Celgene Corp. and Signal Pharmaceuticals. He holds a B.A. degree in Biology from the University of California at San Diego, and a Ph.D. in Molecular Pathology from the UC San Diego School of Medicine. Post-doctoral studies in Medicine and Pharmacology were performed at the University of North Carolina, Chapel Hill School of Medicine, and he was subsequently named the Lineberger Cancer Center Fellow at the UNC Comprehensive Cancer Center.



• **Michael Lang**, Chief Product Development Officer, *Cancer Prevention and Research Institute of Texas (CPRIT)*

Michael Lang leads CPRIT's product development research program, designed to accelerate the progression of new cancer drugs, diagnostics, and therapies from the laboratory into clinical practice. His multi-state experience includes founding and serving as chief executive officer of a cancer diagnostic company, serial entrepreneurship, and managing a portfolio for an early stage investment. Prior to joining CPRIT in November 2015, Lang was the founder and CEO of NanoVision, a cancer diagnostics company. He headed business development at the venture capital-funded wound healing company Gilatech, where he led its novel biomaterial therapy. Lang oversaw a company restructuring as president of Dallas-based Galt Medical, served as a product manager at Johnson & Johnson, and was vice president of business development at BioEnterprise, where he directed the startup and growth of early stage firms. Lang has a bachelor's in biomedical engineering from Northern Arizona University and a master's in business administration from Arizona State University.



• **Thorsten Melcher**, Senior Director, New Ventures & Partnerships, *Johnson & Johnson Innovation*

Thorsten is Senior Director for New Ventures Johnson & Johnson Innovation. He focuses on establishing and guiding collaborative partnerships, and on facilitating new company formation. Previously, Thorsten led the biomedical efforts at Varian Medical Systems where he established a spin-out company to integrate radiotherapy with targeted cancer therapeutics. Before Varian, Thorsten served in several R&D, business development and operational and roles at AGY Therapeutics, EnVivo Pharmaceuticals and Saegis Pharmaceuticals. He received his MS in Biochemistry from the University of Hannover, Germany and his PhD in Molecular Neurobiology from the University of Heidelberg, Germany. He was a postdoctoral fellow at UCSF.



• **Colin Widen**, CEO, *Boston Innovation Capital* 

Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the firm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.



• **Jayson Rieger**, SVP of Business Development & Portfolio Management, *PBM Capital*

Dr. Jayson M. Rieger, Ph.D, MBA, is currently the SVP of Business Development & Portfolio Management for PBM Capital, LLC, where he supports new investment evaluation, deal sourcing and provides technical and business support for portfolio companies. Dr. Rieger has more than 10 years experience in cross-functional scientific and business leadership roles spanning business development, research operations, drug discovery and product development in the life sciences industry. Most recently he served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation. Dr. Rieger has also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc., prior to its acquisition by Forest Labs in 2011. Dr. Rieger served as the Vice President of Lead Development at Adenosine Therapeutics, LLC, from prior to its acquisition by Clinical Data in 2008. Dr. Rieger has delivered a number of invited lectures at universities and scientific conferences and has served as a key team member in multiple development programs ranging from discovery stage research to Phase III clinical trials. He was the recipient of more than 10 federal grants, serving as both principal and co-investigator on efforts targeted towards evaluating adenosine receptor agents in a variety of disease indications.



• **Julia Belaya**, Corporate Partnerships, *Plug and Play*

Julia leads the Corporate Partnership program for the Healthcare Innovation Platform at Plug and Play, the largest global technology accelerator. Plug and Play is located in the heart of Silicon Valley and is an early investor in companies such as Paypal, Dropbox, and LendingClub. Julia works to connect corporations with an interest in innovation in the health space with portfolio start-up companies to possibly engage in pilots, licensing deals, strategic partnerships and investment opportunities. Prior to Plug and Play, Julia worked at a boutique wealth management firm and was a consultant at Deloitte.



• **Robert Hatcher**, President & CEO, *Cockrell Interests*


Mr. Hatcher serves as the President and Chief Executive Officer of Cockrell Interests LLC, Pinto Investment Partners and related companies. Mr. Hatcher also serves as Chairman of the Finance Advisory Committee for PTV Healthcare Capital, L.P. and Pinto America Growth Fund, L.P. and on the Board of Directors of certain Pinto Group portfolio companies, including Alloy Merchant Finance, First Continental and Clarity Medical Systems. Cockrell Interests is a private, diversified investment management company with interests in public and private equity, energy, real estate, venture capital, aviation and agriculture. Cockrell Interests maintains a disciplined, long-term approach to investing and enjoys a long history of developing and operating businesses based on fundamental values. Prior to joining Cockrell Interests in 2001, Mr. Hatcher founded and served as Managing Director of Citywest Ventures, a Houston-based private equity and financial advisory firm. During 1999 and 2000, Mr. Hatcher served as Managing Director of Corporate Strategy and Development of Metamor Worldwide, Inc., a multi-national information technology professional services firm. Mr. Hatcher also served on the Executive Committee of Metamor and as President of its venture capital group. Prior to joining Metamor, Mr. Hatcher was a corporate finance and securities partner in Vinson & Elkins LLP.



• **Sean Kearney**, Managing Director, *Three Leaf Ventures*

Sean co-founded Three Leaf Ventures with Pat and Kiki Broe with the firm belief that the way we manage our health as individuals is in need of a paradigm shift, thus resulting in a venture investment portfolio focused exclusively on technology poised to transform how we manage our health. Prior to joining the Broe Group and founding Three Leaf Ventures, Sean traded in international derivatives markets for a fortune 500 manufacturer in Cleveland, Ohio. Sean returned to his birth state of Colorado after graduate work focused on private investment markets. He holds an MBA from the Ohio State University, and a B.S. in Finance from Miami University in Oxford, Ohio. He maintains his drive by running 90 miles per week in preparation for his next marathon, or through hiking with his wife and border collie.



• **Jit Patel**, VP of Research & Business Development, *Juvenile Diabetes Research Foundation (JDRF)* 

Dr. Jit Patel is Vice President of Research & Business Development at Juvenile Diabetes Research Foundation (JDRF). JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to facilitate development of novel therapeutics to better treat and cure type 1 diabetes and its complications. Currently JDRF is currently sponsoring more than \$568 million in research, advocacy and development in 17 countries. As head of Research Business Development, Dr. Patel is responsible for establishing and managing strategic, mission-aligned industry R&D partnerships with biopharmaceutical and medical device companies. Dr. Patel obtained his B.Sc. and PhD from Kings College, University of London. He did his postdoctoral training at the NIH, and subsequently joined AstraZeneca Biopharmaceuticals. After holding several key leadership positions with increasing responsibilities in drug discovery, Dr. Patel transitioned to pursue a career in business development. As a scientist, Dr. Patel has authored more than 80 scientific papers and edited two books in Neuroscience. As a business development professional, he has executed a substantial number of strategically transformative deals across the R&D value chain and industry sector.

• **Debra Miller**, Founder & CEO, *CureDuchenne*



Debra Miller co-founded CureDuchenne in 2003 with her husband, Paul, after their only son was diagnosed with Duchenne muscular dystrophy. A respected thought leader in venture philanthropy and medical advocacy, Miller serves as CEO of CureDuchenne. She frequently shares her expertise through op-eds and industry events. Miller relies on her extensive background in sales and marketing to lead CureDuchenne. In addition to overseeing all operations, research and financial resources, Debra works closely with CureDuchenne's Scientific Advisory Board in setting out and implementing the organization's medical and research strategic plans. She also is a voice on various Duchenne review panels, such as the Department of Defense Duchenne Muscular Dystrophy Research Program and TREAT-NMD's international review board TACT. Miller has led CureDuchenne's successful venture philanthropy programs and is the architect of CureDuchenne Ventures LLC, a new, for profit entity created to attract significant research funding to Duchenne research. Miller has also been recognized often for her organization's innovative approach to fighting Duchenne. She won Orange County Business Journal's 2015 Women in Business Award and was a finalist for EY's 2014 Entrepreneur of the Year in Orange County.

• **Grace Pavlath, Ph.D.** Senior Vice President & Scientific Program Director, *Muscular Dystrophy Association*



Grace Pavlath, Ph.D. joined the MDA in 2014. She provides scientific leadership for MDA's research department, which is focused on delivering effective therapies for more than 40 muscular dystrophies and ALS through funding projects in academia and industry. Prior to joining MDA, she was a tenured professor at Emory University in Atlanta. For almost 30 years Dr. Pavlath has established herself as a leading researcher in cellular and molecular mechanisms that are critical for muscle growth and repair in health and disease. Dr. Pavlath is a graduate of the University of California, Berkeley, received her Ph.D. in Pharmacology from Stanford University and did further post-doctoral training at Stanford University.

• **John Parker**, Trustee, Managing Director (CH Innovations), *Charles H. Hood Foundation*



John Parker is Vice President of the Board of Trustees of the Charles H. Hood Foundation, a Boston based private foundation focused on children's health. He is also Founder and Managing Director of CH Innovations, LLC, the Hood Foundation's program-related investment (PRI) subsidiary. CHI seeks to further the Foundation's philanthropic goals by using PRIs to support companies with potentially high-impact biomedical solutions targeting pediatric populations as they navigate the "Valley of Death." John has over 20 years of experience making and managing alternative investments. He is currently Managing Director of Tidal Capital Management, a family office and hedge fund. Previously, he was Chief Investment Officer of Xylem Investments, an international private equity firm. He also worked as a management consultant at Cambridge Strategic Management Group and Booz Allen Hamilton. The early part of his career was spent as a merchant banker in Tokyo. He has served as a board member, observer or advisor to multiple companies. John graduated from Dartmouth College and earned an MBA from the Amos Tuck School of Business Administration at Dartmouth.

• **Rick Jones**, Director, *Broadview Ventures*



Frederick "Rick" Jones, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Rick founded Spordiff Therapeutics, which is developing a small molecule to prevent *C. difficile* infection. Previously, Rick was CEO of Anchor Therapeutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets.

• **Richard Soll**, SVP, International Discovery Service Unit, WuXi AppTec 



Dr. Richard Soll is Senior Vice President, International Discovery Service Unit (IDSU) at WuXi AppTec and leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi's comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world's two leading biotech hubs. Dr. Soll's contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy elbasvir, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator and has been an SAB member to biotech companies and advisor to entrepreneurs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard.

• **Jun Lu**, VP & Managing Partner, Vesalius Ventures



Mr. Jun Lu currently serves as the vice president and managing partner of Vesalius Ventures, a Houston based venture capital accelerator focusing on early stage companies in telemedicine, mHealth, and other medical technology in the US and China. His investment and incubating projects include, a leading cardiac monitoring service provider in China, Tianjin Guangyi Medtech, JSA Health Telepsychiatry, LifeBot, SALUS, etc. He also served several US medical technology companies as an advisor, to help them expand business in China. Mr. Lu is also working with the American Telemedicine Association and the Tianjin Municipal Government and the Tianjin Binhai High-tech Industrial Development Zone, to develop the first China International Exhibition of telemedicine technology. Mr. Lu also leads the development of VesaliuX, a cross-border healthcare business accelerator focusing on developing market entry and investment opportunities in China for U.S. healthcare technology companies. The company is also in the process of raising a seed-fund to invest in early stage companies. Prior to Vesalius, Mr. Lu Jun worked as a senior business analyst at a Healthcare IT company in Houston. He also served as an intern security analyst at BOCI-Prudential Asset Management Company, a Hong Kong base firm and as a sales engineer at Focus Technology in China.

• **Lu Zhang**, Managing Partner, NewGen Venture Partners



Lu Zhang is the Managing Partner of NewGen Venture Partners. Prior to starting NewGen, she was a Venture Partner at Fenox Venture Capital and participated in over 20 investments. Lu was also the Founder and CEO of Acetone Inc. (acquired 2012), a start-up focused on developing device technology for the early diagnosis of Type II diabetes. She has also worked as a consultant at the United Nations Industrial Development Agency and was the former head of International Student Entrepreneurs Union in China. Lu received her M.S. in Materials Science and Engineering from Stanford University and holds over a dozen patents.

• **Masashi Kiyomine**, Investment Director, Mitsui Global Investment



Masashi has been an Investment Director since April 2012 and drives MGI's Life Sciences investment activity as Global Life Sciences Team Leader. His investments focus on the intersection of healthcare and technologies/services that improve health outcomes and address inefficiencies in the healthcare system. He began his career investing in early stage medical device startups, and later started the digital health/ healthcare services practice at MGI. He serves or served as a board member of goBalto, ContinuumRx Services, ChangeHealthcare, and Arravasc, and his other investments and involvements include Symic Biomedical, MC10, NxThera, Optiscan, Cardiovascular Systems Inc. and Ekos. He joined MCVP in June 2004. He received his B.A. in Engineering and Asian Studies from Dartmouth College.

• **Yuwen Liu**, Founding Partner, BOHE Angel Fund



Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by WuXi AppTec, Hengrui, Simcere, TigerMed and BGI, etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. Before she set up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies. She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation. She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.



• **Robert Tucci**, Managing Director, *Texas Halo Fund* 

Rob is an active investor and nine-year member and Life Sciences Chair at the Houston Angel Network, the 4th largest in the USA. He is a member of the University of Houston's Cougar Fund, serving as a judge and has lectured in the Bauer School of Business. At the \$6.5M Texas Halo Fund, Rob directs investments generally within the biotechnology, life sciences and energy sectors. He is the founder (1996) of Yardley Group, LLC, an active chemical development and export business serving South America. Rob has served as a judge at the Rice University Business Plan Competition, the New Orleans BioInnovation Center, and Oklahoma's Governors' Cup. He is an investment speaker to the University of Texas McComb School, Rice University's Jones School, and adviser to the National Space Biomedical Research Institute. Rob serves on the Board of Directors of Adient Medical, Inc. and as a General Partner of Houston Health Ventures. A chemist/MBA, Rob resides in Houston with his physician wife.



• **David Franklin**, Co-Founder, Managing Director, *Houston Health Ventures*

David has over 10 years of experience in business management consulting, corporate strategy, operations, marketing, business development, sales, and venture capital. He currently serves as Executive Vice President at Consumer Media Network (CMN), LLC, a digital marketing and lead generation company. Previously, David was Co-founder and Managing Partner at DCF Ventures, LLC. DCFV provided feasibility analyses, market analyses, company incorporation, university licensing, startup consulting, interim management, grant writing, and fundraising services. In this role, David also served as CEO pro tem for CytoScale Diagnostics, LLC, RadMit Pharma, LLC and FloVision, LLC. At DaVita, Inc. David served as a Corporate Strategy Associate where he formulated market growth and strategic operations plans, led the national clinical outcomes team for @Home, increased IT and clinical research resources and created new clinical reports/scoring. He also acted as Interim VP of Marketing for @Home. Prior to DaVita, David was a Business Management Consultant at Accenture. David holds his MBA from UCLA Anderson where he was a Venture Capital, Young Presidents' Organization (YPO), and Technology Innovation and Commercialization Partners (TIP) fellow. David received his B.S.E. in Bio-Medical & Electrical Engineering with minors in Economics & Chemistry from Duke University.



• **Chuck McCoy**, Founder & Executive Director, *North Texas Angel Network*

North Texas Angel Network (NTAN) is a group of over 50 accredited investors that seek 4 or 5 startups per year that have the potential to build real wealth and create additional entrepreneurial families in Texas. NTAN was started in 2008 and the members have invested about \$8MM in 20 or so companies as a part of a formal and rigorous process. Prior to starting NTAN Chuck spent a year as Director of Commercialization Programs at the North Texas RCIC. The Texas Emerging Technology Fund was actively funding technology start-ups and the RCIC brought many universities based companies to the fund. This was his first major experience outside of building and delivering enterprise software. After learning the commercial software business at Arthur Andersen & Company, Chuck spent 20 years as an independent operator building, selling, and rolling-out software for clients. The primary focus was planning and control systems for manufactures of oil and gas tools, with many QA and Test and Measurement requirements. There were also many projects with the early use of electronic document imaging systems for clients such as AT&T, E-Systems, MCI, and Bell South.



• **Ky Calder**, Board Member, *WINGS - The Washington Medical Technology Angel Network*

Mr. Calder is an active early stage investor and advisor with more than twenty years' experience on both the clinical and product side of medical technology. Mr. Calder currently serves on the boards of Wings, the Northwest's leading medical technology angel network, and Aqueduct Critical Care. Mr. Calder is a member of Alliance of Angels and is a principal at Calder Investment Partners. Prior to becoming an investor Mr. Calder worked for Cadwell Labs, a high-tech medical device company, and Biotronic, a contract clinical services company. Mr. Calder has consulted to medical device companies in the areas of product design and international sales. He served on the boards of Tangent Medical Technologies and the American Society of Neurophysiological Monitoring. Mr. Calder earned his master's degree in technology commercialization from the McCombs School of Business at the University of Texas at Austin.



• **Alan Glowczwski**, Member, *Aggie Angel Network*

Dr. Glow is a graduate of Biomedical Science at Texas A&M University (Class of '85). He attended The University of Texas Health Science Center at Houston, obtaining his Medical Doctor degree in 1989. He graduated with honors becoming a member of Alpha Omega Alpha. After medical school he performed his internship at St. Joseph's Hospital in Houston and began a residency in Physical Medicine and Rehabilitation at the University of Washington in Seattle. After one year in Seattle, Dr. Glow switched to Radiology and completed four years of Radiology training at University of Texas Medical Branch in Galveston. During his last year of residency, he also served as Chief Resident. After completing residency, Dr. Glow joined a private practice Radiology group in Longview where he practiced Diagnostic and Interventional Radiology. During the last four years of his practice he was the Director of Radiology and Managing Partner for Medical Imaging Consultants. Prior to his resignation from his practice, Dr. Glow formed a Startup company named Scepter Medical Devices, LLC with a focus on vascular access in dialysis patients. This company has now morphed into two companies, one Voyager Biomedical Inc. with a focus on vascular access and Scepter Medical Devices Inc with a focus on infection prevention in patients with central venous lines. In addition to founding these startup companies, he has recently accepted a position as Imaging Director at Texas A&M Institute for Preclinical Studies. He is an Angel Investor and part of the Aggie Angel Network, participating in two investment funds called Research Valley Fund and Maroon fund.


DIAGNOSTIC INVESTORS



• **John Walter**, Chief Executive Officer & President, *Alliance for Cancer Gene Therapy* 

In this new role John is charged with meeting the ever-increasing demand for research funding, building brand equity, and exploring investments with industry partners for AGCT, which exclusively supports research in genetic, cell and immunotherapeutic approaches to improve outcomes for all cancers. John served as President and CEO of the Leukemia & Society, an international health agency. He drove LLS's long-range strategic plan with a focus on broadening its base of support and diversifying its revenue sources. John first joined LLS in 1995 as Senior Vice President of Finance and Information Technology. Then, as Executive Vice President of Strategic Alliances and New Business Development, he designed and implemented LLS's Co-Pay Assistance Program, which has provided more than \$200 million to patients. He also oversaw the international merger that created LLS Canada. John directed the launch of "Someday is Today," the branding platform that illuminates how LLS is changing the landscape of cancer. He guided the expansion of the Therapy Acceleration Program, embracing a venture philanthropy approach. John has spoken at congressional events in Washington, and to the international business community. He has been published in numerous journals.

• **Caroline Popper**, President, *BCM Technologies*



Dr. Caroline Popper has 20 years of hands-on biotech/life sciences operating experience. An internist and pathologist, subsequently trained in health economics, she combines this perspective with that gained from managing a wide spectrum of life sciences businesses in diagnostics, devices, and drug discovery. She has extensive diagnostic industry experience. In an 11-year career at Becton Dickinson (BD NYSE), Dr. Popper's global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene; a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. From 2000 to 2002, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the US, Canada, and Europe. Dr. Popper received her MD from the University of the Witwatersrand (South Africa) and her MPH from Johns Hopkins University in Baltimore. She was a Robert Wood Johnson Fellow in Health Care Finance and completed her residencies in Internal Medicine and in Pathology at Johns Hopkins.

• **Tom Hawes**, Managing Director, *Sandbox Industries*



Dr. Tom Hawes is a managing director of the BlueCross BlueShield venture fund. He serves on the boards of directors of AbilTo, HeartFlow, Lumiata, Nexidia, Patientco, Phreesia, Oncology Analytics, and ID Experts and formerly served on the boards of InVivoLink and Wellspring Healthcare. Before joining Sandbox, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC's cardiothoracic surgery department. Tom is on the national advisory board of the Desmoid Tumor Research Foundation. Tom holds a B.A. from Brigham Young University, an M.D. from New York Medical College, and an M.B.A. from Harvard Business School. He is also a Kauffman Fellow.

• **Tom Miller**, Managing Partner, *GreyBird Ventures*



After receiving a degree in Nuclear Engineering from the University of Massachusetts at Lowell, Tom studied Medical Physics at the Harvard/MIT Health Sciences and Technology joint program graduating with a Masters degree in 1982. During his academic career he worked at Los Alamos, the Swiss Institute for Nuclear Research (now the Paul Scherer Institute), Brookhaven National Laboratory, and the Massachusetts General Hospital as a research associate in radiation biophysics. Tom then joined Siemens Medical Systems where, after 9 years, he became the first non-German CEO of a German factory and business unit. He left Siemens after 15 years to become CEO of the global medical operations of Carl Zeiss. Completing a successful turnaround, he joined Analogic Corporation as CEO. After three years and a doubling of the stock price, Tom left to become CEO of LightLab Imaging, a start-up that he helped to establish. Completing a profitable sale of LightLab, Tom re-joined Siemens eventually serving as a member of the operating board of Siemens Healthcare and the CEO of Customer Solutions Division, responsible for 26,000 employees in over 130 countries. Tom co-founded GreyBird in mid-2013 with an investment focus on technologies enabling precision medicine diagnosis.

• **Wouter Meuleman**, Director of Corporate Development, *Illumina*



Wouter is Director of Corporate Development at Illumina, Inc., and a member of the Illumina Ventures teams. Since joining Illumina in 2009, he has also held roles in R&D and Product Development, where he was instrumental in the development of sequencing platforms such as the MiSeq, sourcing and evaluate new technology opportunities, and emerging threat assessment. An electrochemist by training he made his debut in life sciences in 2003 as first hire for Oxford University spin-out Oxamer, a company founded by Lasker-award winner Prof. Sir Edwin Southern, contributing to the development of a benchtop DNA microarray fabrication platform. Following Oxamer's merger with Oxford Gene Technology he continued working alongside Southern, leading R&D on single cell gene expression analysis and novel applications for DNA microarrays. Wouter obtained a joint BSc/MSc in Chemistry from the University of Ghent, Belgium, a PhD in Chemical Engineering from the University of Newcastle, U.K., and an MBA from the University of Cambridge, U.K.



• **Patrick Brennan**, Director of Business Development, *Life Sciences Conference Group* 

Patrick Brennan is the Director of Business Development for the Life Sciences Conference Group, which produces the annual AdvaMed MedTech Conference. In this role, Patrick engages with senior executives, innovators and investors in the global medical technology industry to create unique programs and opportunities for business development and capital formation. Prior to joining AdvaMed, Patrick served as Vice Consul for UK Trade & Investment at the British Embassy in Washington, where he provided strategic market entry guidance to British and American companies, fostered transatlantic commercial partnerships and led ministerial visits and trade delegations. Patrick previously worked for the U.S. Department of Commerce, International Trade Administration on cross-border training and market access programs in Russia, Central Asia and the Caucasus. Patrick holds an MBA from the Middlebury Institute of International Studies at Monterey and a BA from the University of North Carolina at Chapel Hill.



• **Bill Waller**, Lead Counsel, *Varian Medical Systems*

Bill serves as Lead Counsel for Real-Time Tracking Technologies, the Seattle site of Varian Medical Systems, the leading manufacturer of medical devices for treating cancer with radiation. Bill is an active angel investor, personally invested in seven private startups, mostly med tech and biotech companies. Bill is a member of the Board of Directors of Monitor Mask, Inc., a Seattle startup selling FDA-cleared medical devices for measuring CO2 when providing anesthesia, serves on the advisory board of another med tech start up, and is a member of the Investor Committee for WINGS, the Seattle-based med tech angel group. Bill served as a VP for both Seattle-based biotech Dendreon and Novartis, and served in senior roles in the federal government and with FDA law firms. Previously Bill served as FDA attorney in private practice at leading FDA law firms Covington & Venable. Bill also served as Majority Counsel for the US House of Representatives House Oversight Subcommittee with jurisdiction over FDA. Bill received a JD with honors from Harvard Law, and a BA with highest honors from Colgate University. Bill lives on Mercer Island, WA with his wife and children.




• **Sherrie Perkins**, Vice President, Sleep Apnea (New Ventures), *LivaNova*

Sherrie joined Cyberonics in 2000 as Marketing Director for the company's Vagus Nerve Stimulation (VNS) Therapy® franchise and was responsible for developing the pre-launch and launch strategy for the treatment-resistant depression indication, as well as the medical marketing strategy for the drug-resistant epilepsy indication. In 2008, Sherrie transitioned to a newly-created role in New Business Development. In this position, she identified and developed collaborations and partnerships focused on strategically-relevant technologies, IP, and acquisitions to support and accelerate Cyberonics' pipeline and market expansion goals. In 2011, Sherrie was named VP, Marketing & New Business Development. In 2015, Cyberonics and Sorin S.p.A. executed a merger and subsequent creation of a new company, LivaNova PLC. Sherrie led the integration process within legacy Cyberonics and is now responsible for the sleep apnea franchise within New Ventures of LivaNova. She serves as an observer on the Board of Directors for ImThera Medical, Inc. Sherrie holds a Bachelor of Science degree from Mississippi State University and a Master of Arts degree in Management from Central Michigan University.



• **Nicholas Moulras**, Sr. Director New Ventures, *Johnson & Johnson Innovation*

Nick's role within New Ventures focuses on medical device innovation in support of the general surgery, orthopedics, and cardiology businesses. His charge is to identify licensing, collaboration, and investment opportunities highly aligned with J&J business strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders. Nick and the New Ventures team employ a broad array of deal structures in order to best fit the specific needs of the innovation opportunity, as appropriate collaborating with JJDC (equity investments) and JLABS (incubator). Previously he served as PARC's Director of Global Healthcare Innovation and as the Xerox Innovation Group's Healthcare Program Manager. His focus was on developing and executing a high-impact innovation strategy that aligned with the long-term roadmap of the Xerox healthcare businesses by identifying and understanding emerging trends in healthcare and technology. Nick's start-up experience includes founding companies in orthopedics, cardiology, and radiation oncology. He was the CEO of Tarsus Medical - acquired by Integra LifeSciences (IART), and Acumen Medical - acquired by Medtronic (MDT).



• **Suzanne Hagin**, Sr. Marketing Projects Developer, *Air Liquide Healthcare*

Suzanne Hagin is Sr. Marketing Projects Developer for Air Liquide Healthcare, focused on strategic growth of the healthcare business unit in current and future business endeavors, geographically focused on North America. Prior to joining Air Liquide Healthcare, Suzanne was with Merz North America (formerly BioForm Medical) for 7 years in progressive roles in marketing and medical affairs focused on devices and drugs for the aesthetic market. Her other experiences include marketing for diagnostics with Genoptix Medical Laboratory and workforce development with BIOCOM. She holds a Masters in Bioscience from Keck Graduate Institute and a BS in Chemistry from the University of Texas.



• **Angela Shah**, Editor, *Xconomy* 

Angela Shah is the editor of Xconomy Texas. She has written about startups along a wide entrepreneurial spectrum, from Silicon Valley transplants to Austin partying in the '90s tech boom to 20-something women defying cultural norms as they seek to build vital IT infrastructure in a war-torn Afghanistan. As a foreign correspondent based in Dubai, her work appeared in The New York Times, TIME, Newsweek/Daily Beast and Forbes Asia. Before moving overseas, Shah was a staff writer and columnist with The Dallas Morning News and the Austin American-Statesman. She is a graduate of the University of Texas at Austin and a 2007 Knight-Wallace Fellow at the University of Michigan. With the launch of Xconomy Texas, she's returned to her hometown of Houston and now writes about innovation in the Lone Star State.



• **Andrew Offer**, CFO & Managing Director, *Scientific Health Development*

Andrew Offer joined SHD in 2007 and is a Managing Director and the Chief Financial Officer. Mr. Offer also serves as the Chief Financial Officer for multiple portfolio companies. Prior to joining SHD, he was a senior analyst and associate at Dallas-based Value Management Group (VMG Health). At VMG Health, Mr. Offer focused on business valuation exclusively in the healthcare industry. Mr. Offer graduated Magna Cum Laude with multiple honors distinctions earning a B.B.A. in Finance from the Mays School of Business at Texas A&M University. In addition, Mr. Offer earned the Chartered Financial Analyst (CFA) designation in 2009.



• **James Eadie**, Partner, *Santé Ventures*

James joined Santé Ventures in 2010. Previously, James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio. He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander. He separated honorably as a Major in 2008. James received his MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women's Hospital.




• **Phillip Sanger**, Managing Partner, *Texo Ventures*


As an active investor and the founder of multiple healthcare ventures, including a publically traded Medicare-Advantage Health Plan, Phil understands what it takes to build a successful healthcare company. After working for over 30 years as a healthcare entrepreneur and a physician, he also has a first-hand understanding of the complexities and challenges of the healthcare system. His vision for hospitalist medicine and medical management strategies can be found in national publications like Managed Healthcare Executive, Health Insurance Underwriters, The Hospitalist Magazine, and Disease Management Advisor. Phil focuses on Managed Care & Benefit Design and Technology-Enabled Health Services. He currently sits on the board of TEXO portfolio companies Televero Health, Precedent Health and Employer Direct. He also funded and launched the Sanger Learning Center, the main resource for academic support at the University of Texas at Austin. In 2000, Phil helped launch HealthSpring and grow it to a successful \$366 million Initial Public Offering (IPO) in 2006. In 2011, HealthSpring (NYSE: HS) was acquired by Cigna (NYSE: CI) for \$3.8 billion after generating more than \$3 billion in revenues the previous year.



• **Steve Banks**, Venture Partner Emeritus, *S3 Ventures*

Steve served as a Venture Partner of S3 Ventures for over 10 years (from founding in 2005 through 2015). Steve is a pioneer in venture capital. He began his distinctive career by backing legendary venture capital firm Kleiner Perkins and co-investing in several of their outstanding companies — such as Genentech, Hybritech and Tandem — while serving as vice president of venture capital at The Hillman Company. Steve is also a pioneer in the life sciences. In 1988, he became president of BCM Technologies ("BCMT"), where he was involved in the formation of more than 30 new technology companies spun out of the Baylor College of Medicine ("BCM"), including: Lexicon (LEXG), GeneMedicine (VLTS), ForeFront (SKIL), Triplex (AGEN), PrimaCis (MDLIQ) and Zonagen (ZONA). He also established BCMT's venture fund and led BCMT's venture advisory board, consisting of prominent investors such as Oxford Biosciences, Domain Associates, Versant, VenRock, EuclidSR, ARCH, J&J Development and Polaris. Steve is the recipient of the 2012 Dai-Shan Wong Memorial Achievement Award from Gulf Coast Medical Device Manufacturers. This annual award is presented to the person who exemplifies the same spirit and enthusiasm as that of Dia-Shan Wong. Mr. Wong was dedicated to the growth and regulatory education of Houston's life science community.



• **Nicole Fisher**, Founder & CEO, *HHR Strategies* 

Nicole Fisher is the founder and CEO of HHR Strategies, a health and human rights focused advising firm. She is also a senior policy advisor on Capitol Hill and expert on health reform, technology and brain health - specifically as they impact vulnerable populations. Fisher curates a monthly international dinner series, "A Seat at the Table," bringing together thought leaders for an off-the-record discussion of moving health policy and planning forward. She also runs the nonprofit Global Brain Health Coalition and is pursuing a doctoral degree in health policy at the University of North Carolina. Her writing has appeared in numerous journals and publications, and her talks can be found on the United Nations website and various news outlets. Before pursuing her PhD, Fisher earned her master's degree in public policy from the University of Chicago and her undergraduate degree from the University of Missouri. Her health care and policy work at those institutions emphasized underserved populations, women's and children's issues, and brain health. She serves on several boards for domestic and international health organizations and frequently speaks on health reform, innovation, human rights, and the context surrounding health.



• **Erik Halvorsen**, Director, *Innovation Institute at Texas Medical Center*

Erik Halvorsen became the Director of the Innovation Institute at the Texas Medical Center in November of 2015. In that role, Erik is responsible for the TMCx and TMCx+ incubators, the Biodesign program and is working to launch a TMC investment fund in 2016. He leads a cross-functional team responsible for the selection, incubation and acceleration of early stage healthcare companies and manages a 100,000 sq. ft. open innovation facility for ~30+ companies in healthcare, life science and digital health. Erik strives to broadly engage TMC network of 35+ hospitals, medical schools, universities, professional programs and clinics on all aspects and stages of innovation while leveraging a network of investors, entrepreneurs, advisors, mentors, operational and technical talent and service providers to support TMC start-ups. Prior to joining TMC, Erik Halvorsen was the Senior Executive Director for Technology Transfer & Industry Collaborations (TTIC) at Tufts University and Tufts Medical School where he led a team and a series of initiatives to translate research and innovation into new commercial entities and products. From 2007-2014, Erik served as the Director of Technology and Business Development for Children's Hospital Boston (#1 ranked pediatric hospital by U.S. News and World Report). From 2007-2014, Erik served as the Director of Technology and Business Development for Children's Hospital Boston (#1 ranked pediatric hospital by U.S. News and World Report). There he built and the Technology Innovation Development Office (TIDO) which was responsible for translating Children's renowned laboratory and clinical research into devices, therapeutics, diagnostics, and informatics products that could benefit patients around the world. This included managing teams responsible for intellectual property, technology transfer, business development and clinical trials. He also started and was the managing partner for the first translational investment fund at Boston Children's investing ~\$10M over the first 7 years of the fund.



• **Judi Manis**, RVP of Strategic Relations & BD, *Internet of Things Healthcare, AT&T Foundry*

Judi Manis is the Regional Vice President of Healthcare Strategic Relations and Business Development in AT&T's Internet of Things Healthcare Group. Judi leads a team that is focused on the commercialization of health innovations, utilizing AT&T's vast product portfolio. Additionally, Judi and her team are responsible for cultivating strategic relations within the healthcare industry for potential collaboration opportunities. She brings to her role a wealth of knowledge, having held a variety of leadership positions in the healthcare, mobility, entertainment and financial services vertical markets within AT&T. A native Californian, Judi earned her BA degree in Marketing/Business from California State Polytechnic University at San Luis Obispo. She resides in Claremont, California with her husband, Bill, the City Manager of Rosemead, Ca. and has two grown children: Krista, a Manager of Development at Viceland Television in Brooklyn, NY and Kyle, a Manager with Apple Retail Inc. in Xiamen, China.



• **Lesley Stolz**, Senior Director of Transactions, *Johnson & Johnson Innovation*

Dr. Stolz has 18 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. Prior to joining the transactions group within Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.

HEALTHCARE IT INVESTORS

TRACK 2



• **Joe Cunningham**, Managing Director, *Santé Ventures* 

Prior to founding Santé, Joe was a healthcare Venture Partner with Austin Ventures and was previously the Vice Chair of the Ascension Health Ventures investment committee. He is also the former Chief Medical Officer of the Providence Health System and Executive Director of the 300-physician Providence Health Alliance, both of which belong to the Ascension Health system. He has extensive management experience and is recognized nationally for his expertise in healthcare delivery systems, physician associations and compensation models. Joe currently serves on advisory boards for both Health Services Corporation (BC/BS) and United Healthcare. He is board certified in both Internal Medicine and Quality Assurance and Peer Review. Joe received his BS and MD degrees from Texas A&M University and his MBA from Baylor University.



• **Aaron Nelson**, General Partner, *dRx Capital*

Aaron is a General Partner at dRx Capital AG, the joint investment company of Novartis Pharmaceuticals and Qualcomm Technologies. In recent years, Aaron has worked on technology strategy for clinical trial teams within Novartis. This work has lead him to conclude that mobile, cloud and Health IT technologies provide transformative opportunities in the clinical research and pharmaceutical industries. Aaron has lead projects building upon these themes across multiple Business Units within Novartis, often by collaborations or investments in early-stage partner companies. Previous roles at Novartis included, Strategic Project Leader in the Digital Development team (formerly known as Trials of the Future) and Group Head in the Discovery and Investigative Safety organization. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institute, and completed his undergraduate studies at Cornell University.



• **David Orlandella**, Managing Director, *ORIX Ventures*

David Orlandella is a Managing Director for ORIX Ventures. His primary focus is on new deal origination and strategic business development for healthcare investments. Prior to joining the ORIX USA team, Mr. Orlandella was a Managing Director for Fifth Street Asset Management, where he was responsible for origination and direct investments for the firm's Technology Lending Group. In addition to his direct investing business, he also helped to drive new opportunities to access capital for additional asset management and growth. Before his time at Fifth Street Asset Management, he served as a Principal for ORIX USA's Corporate Capital division, focused on debt and equity investments in technology and healthcare. Prior to his time at ORIX USA, Mr. Orlandella was a direct venture investor and Managing Director at Enhanced Capital Partners and Redwood Ventures where he successfully executed investments, buyouts and growth financings focused in the technology and healthcare industries. Mr. Orlandella earned his Bachelor of Arts in Economics from Bates College, and later studied Telecommunications at the University of Denver. Mr. Orlandella serves on the advisory council for the Jindal School of Management at the University of Texas at Dallas and has been an active member of the Association for Corporate Growth and the National Venture Capital Association.



• **Dennis Deppenbusch**, Director, New Ventures Initiative, *Blue Cross and Blue Shield of Kansas*

Dennis is responsible for the direction, coordination, evaluation and management in developing and leading strategic investment for BlueCross BlueShield of Kansas. The focus of the initiative is to develop a \$50 Million portfolio of investments that, as a whole, are expected to be integrated into the company as part of its overall long-term strategy. Previously, Dennis worked with several high performing teams to fund, develop and grow start-up enterprises in health, banking and IT; domestically and worldwide.



• **Ulili Onovakpuri**, Venture Partner, *Fresco Capital*

Uririadiakoghene "Ulili" Onovakpuri is a Venture Partner at Fresco Capital and is involved in all aspect of investment operations with a specific focus on digital health and health tech. Previously, she was Director of Global Programs for Village Capital, where she led the organization's Global Accelerator Program. While in business school, Ulili founded LifeKIT, a Mhealth solution for rural communities. Before business school Ulili served as an Investment Analyst at Kapor Capital where she identified and evaluated early-stage healthcare companies. Ulili has an MBA and a Health Sector Management Certificate from Duke University's Fuqua School of Business and a B.A. in Interdisciplinary Studies with a concentration in Business and Health in Global Societies from the University of California, Berkeley.



• **Leo Linbeck III**, Chairman & Founder, *Fannin Innovation Studio* 

Leo Linbeck III is the Chairman and Founder of Fannin Innovation Studio. Leo is also President and CEO of Aquinas Companies, LLC, which sponsored Fannin for eight years to validate its model before bringing in outside investors for scale-up. Leo graduated from the University of Notre Dame with both Civil Engineering and Liberal Arts degrees and received a Masters in Engineering from the University of Texas. He earned his MBA from the Stanford University Graduate School of Business, graduating as the only student in its history to be both Valedictorian and winner of the Arbuckle Award (the person voted by his classmates to have made the greatest contribution to the school). For the past decade, Leo has served on the faculties at the Stanford and Rice Graduate Schools of Business.

• **Blair Kessler**, Manager, *Healthbox*



Blair Kessler is a Manager for Healthbox in their Chicago office, leading the Studio business and operations of accelerator programs in 6 markets globally across the US, UK and Israel. Before joining Healthbox, Blair spent two years as a consultant with McKinsey & Company as part of their Hospital Systems & Services practice. Through his time at McKinsey, Blair served leading private and public organizations across the healthcare ecosystem, throughout the US and Australia, on both growth strategy and operations based topics. Previous work experience includes middle-market private equity (Braxos Capital), Fortune 500 healthcare corporate strategy (DaVita), technology start-up (GoSoapBox) and teaching English in Zanzibar, Tanzania (Outreach Zanzibar). Blair holds a Bachelor's degree in Economics and Entrepreneurship from Northwestern University. He remains actively involved on campus, serving as a senior advisor to the The Insight Group, Northwestern Universities' largest mentoring organization, which he founded as an undergraduate.

• **David Huizenga**, Co-Founder, President & CEO, *TAO Life Sciences*



David E. Huizenga cofounded and currently manages Tao Life Sciences LLC, an early stage life sciences technology development and investment company. Mr. Huizenga has been on the founding team of numerous life science companies, including involvement in successful acquisitions and exits. Mr. Huizenga has served in a variety of corporate management roles including currently, in his role for Tao Life Sciences, as Interim Chief Executive Officer for two of its portfolio companies: Klaren Technologies Inc., a company with novel sterilization technology to fight healthcare acquired infections in developed and underdeveloped countries around the world, and Moterum LLC, a patient mobility and rehabilitation company whose founding product is aimed at retraining stroke patients to relearn how to walk normally. Previously, Mr. Huizenga has served as the Chief Technology Officer of Zirus, Inc. where he was engaged in management of the Zirus patent portfolio, licensing, and competitive intelligence. Mr. Huizenga was a leader in the translation of the company's science strategy to its patent and business strategy. Before joining the Zirus team, Mr. Huizenga was a partner and the founding member and head of the Patent Team at Arnall Golden Gregory, and prior to this he was a shareholder, and the Chief Financial Officer and Vice President of Venture Investment at Needle & Rosenberg, PC. Mr. Huizenga serves on numerous corporate and non-profit boards.

• **Dianne Carmichael**, Managing Director, *MaRS Discovery District*



Dianne is the managing director of MaRS Health Venture Services and Health Innovation. She works closely with MaRS Health Systems, MaRS EXCITE and MyHealth teams to drive health system transformation, as well as with MaRS Health advisors, volunteers and partners to grow the footprint of MaRS Health. Dianne brings over 25 years of senior executive and CEO experience across four industry sectors: healthcare, technology, financial services and consumer packaged goods. She is an entrepreneur, intrapreneur and startup investor. Dianne's previous experience includes positions as the president of Best Doctors Inc., and founder and president of UHN Solutions at University Health Network. She has significant board experience and is currently vice-chair, board of directors, Holland Bloorview Kids Rehab Hospital; board member at Patients Canada, Canadian Association for People-Centred Health; and is on the advisory board to the Dean, Faculty of Health at York University. Prior to moving into the healthcare sector, Dianne built a high-net-worth portfolio management company, which was sold to a major financial institution. She was vice president at TD Bank before becoming Chairman and CEO of Guardian Capital's Worldsource Financial Management, creating and overseeing four divisions nationally, and ultimately growing the business to over \$8 billion in assets.

• **Hubert Zajicek**, CEO & Co-founder, *Health Wildcatters*



Hubert Zajicek, MD, MBA, is CEO & Co-founder of Health Wildcatters, a healthcare seed fund & accelerator in Dallas, TX. Health Wildcatters provides mentorship, capital and guidance to up to 12 healthcare related startups during an intensive 3 month program which culminates in a pitch day. The fund has invested in 32 healthcare startups, which have attracted over \$12M in capital in less than 2 years. Dr. Zajicek has extensive experience with startups and is an active speaker, panelist and thought leader on healthcare startups, entrepreneurship, financing & healthcare. He serves as advisor, mentor and board member on various organizations and startup companies. He was managing director – medical technology at NTEC (North Texas Enterprise Center), where he ran what eventually became the Southwest's largest medtech investment conference, showcasing startups that attracted in excess of \$300M. Prior, he was on faculty at UT Southwestern, as an NIH funded principal investigator, in the Departments of Internal Medicine and Cell Biology. He has an MD from the University of Vienna and an MBA from SMU.

CONNECTED CONSUMER HEALTH

TRACK 2

• **Steve Welch**, Founder, *DreamIt Ventures* 



Steve started his first big entrepreneurial success, Mitos, in 2001. Without ever raising outside money Steve built Mitos into a global company in the biotech manufacturing field prior to selling it in 2007 at the age of 29 to a Fortune 500 company. Under Steve's guidance Mitos developed several critical innovations and patents which transformed the manufacturing process of biological drugs and vaccines and allowed Mitos to develop a global sales and distribution network. Following the sale of Mitos, Steve co-founded DreamIt Ventures, a new business accelerator model. Forbes recently ranked DreamIt the #3 accelerator in the world. The successes and efficiency of DreamIt have been remarkable. Companies that have come out of DreamIt include Scavenger, SeatGeek, Notehall, Adaptly, MindSnacks and over 125 others. DreamIt is now running programs in Philadelphia, New York, Austin, Baltimore, and Tel-Aviv, Israel and turning out 50+ technology companies per year. From this experience, Steve has worked with hundreds of early stage entrepreneurs to turn their dreams into reality.

• **Marcia Dawood**, Managing Partner, *BlueTree Allied Angels*



Marcia Dawood is a Managing Partner at BlueTree Capital Group leading the Due Diligence and Education committees as well as managing the Enova Angel Fund. She is also a Managing Director within the Golden Seeds angel network that focuses on women-led companies. She has taken an active role in serving as the syndication lead between several regional and national groups collaborating and optimizing deal flow and due diligence information. Marcia also serves on the Board of the Angel Capital Association (ACA), an organization that represents over 12,000 accredited investor members, 220 angel groups and accredited platforms that have invested in well over 10,000 entrepreneurial companies. During her graduate studies, her group acquired the franchise rights to a new sports team. She served on the Board of Directors and managed financial and legal matters for the organization. This gave her experience as an entrepreneur from the start through the exit of a business. She also sits on several advisory/boards including life science company, Abililife, working on a "smart" back brace for Parkinson's patients. Marcia is an experienced speaker at many national and international venues. Prior to becoming an active investor, she was with Kaplan Higher Education 16+ years.

• **Stefanie Dhanda**, Senior Director of Consumer Scientific Innovation, *Johnson & Johnson Innovation*



Stefanie is Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, Boston. Stefanie leads Consumer sector efforts to manage a portfolio of innovative external partnerships, collaborations and investments, which currently reach across broad and diverse sectors such as oral care, compromised skin, baby and maternal health, personal care and beauty, an OTC platform anchored in pain relief, cough/cold, and digestive health, as well as digital health platforms. Previously, Stefanie was a Managing Director at Stonebridge Associates, a Boston-based investment banking firm that she helped found in 1996. She has over 20 years of experience working with companies in the consumer and healthcare sectors, leading M&A engagements, raised capital, defined business and financial strategy, performed complex due diligence and negotiated strategic alliances. In addition, Stefanie was independently consulting with startup and early-stage companies focused on the nutrition, health and wellness sector.

• **Sean Kearney**, Managing Director, *Three Leaf Ventures*



Sean co-founded Three Leaf Ventures with Pat and Kiki Broe with the firm belief that the way we manage our health as individuals is in need of a paradigm shift, thus resulting in a venture investment portfolio focused exclusively on technology poised to transform how we manage our health. Prior to joining the Broe Group and founding Three Leaf Ventures, Sean traded in international derivatives markets for a fortune 500 manufacturer in Cleveland, Ohio. Sean returned to his birth state of Colorado after graduate work focused on private investment markets. He holds an MBA from the Ohio State University, and a B.S. in Finance from Miami University in Oxford, Ohio. He maintains his drive by running 90 miles per week in preparation for his next marathon, or through hiking with his wife and border collie.

• **Huan Le**, Co-Founder, Managing Director, *Houston Health Ventures*



Huan Le has over 13 years of experience securing financing, conducting due diligence, handling legal matters, negotiating, and executing acquisitions. Huan is an expert at collaborating to implement new structures, processes and positions to scale growing companies. He currently performs such roles in his current position as Chief Administrative Officer and General Counsel at DiCentral Corporation. Huan is also Co-Founder at Medifr, Inc. He is also Founder, Director, & Advisor for Caphin, Inc., Huan wrote the business plan, acquired the financing, and assembled the team that produces, distributes, and markets a ready-to-drink beverage (Vietnamese Iced Coffee). He earned his law degree from the University of Texas School of Law. Huan received his Bachelor of Arts International Relations & Biology from the University of Southern California where he received a four year, full tuition academic merit Trustee Scholarship, was a member of the Baccalaureate/Medical Doctor (BA/MD) Program with guaranteed admission to USC Medical School, and was a National Merit Scholar. Huan is an advisory board member of Asia Society and an alumni of Asia 21. He is also a director of the Ek Disha Foundation. He enjoys food and is a member of the food council for Fearless Critic, a restaurant guide, and has written restaurant reviews for numerous publications.



Workshops

<p>8:00 AM - 8:50 AM</p>	<p>FUNDRAISING BOOT CAMP</p>		<ul style="list-style-type: none"> • Danielle Silva, VP of Business Development
<p>9:00 AM - 9:50 AM</p>	<p>R&D TAX CREDITS</p>		<ul style="list-style-type: none"> • Jacob Setterbo, Director of Grants • Bob Stabell, Senior Director
<p>10:00 AM - 10:50 AM</p>	<p>HOW TO VALUE YOUR STARTUP</p>		<ul style="list-style-type: none"> • Teresa Gonzalo, Business Analyst & BD USA
<p>11:00 AM - 11:50 AM</p>	<p>CROWDFUNDING & REG A+</p>		<ul style="list-style-type: none"> • Eric Orsic, Partner, Chicago • Gary Emmanuel, Partner, New York
<p>1:00 PM - 1:50 PM</p>	<p>TALES FROM THE ROAD</p>		<ul style="list-style-type: none"> • Michael Redman, CEO, <i>Oncolix</i> • Rob Hedequist, President & COO, <i>Kineta</i> • Larry Cohen, CEO, <i>Glycotest</i> • Roger Nolan, President, <i>BioKier</i> • Jonathan Cohen, CEO, <i>20/20 GeneSystems</i>
<p>3:00 PM - 3:50 PM</p>	<p>BOSTON INNOVATION CAPITAL</p>		<ul style="list-style-type: none"> • Colin Widen, CEO
<p>4:00 PM - 4:50 PM</p>	<p>BRANDING & MESSAGING</p>		<ul style="list-style-type: none"> • Dennis Ford, Founder & CEO



• **Danielle Silva**, VP of Business Development, *Life Science Naiton*
Workshop: Fundraising Boot Camp

Danielle is a founding partner of Life Science Nation and helps companies developing therapeutics, medical devices develop their outbound marketing campaign and identify fundraising partners. Previously, Danielle was a marketer for a multi-family office with over \$4 billion in assets under management. Danielle first started her career as a research analyst at Brighton House Associates, assisting fund managers in the hedge fund, private equity, and venture capital space raise money via institutional alternative investors. Danielle has been quoted in a variety of publications in the alternative investment space including the Wall Street Journal, the Financial Times, and Jim Cramer's "The Street". Danielle received her Bachelor's degree in Economics and Policy Studies from the Maxwell School at Syracuse University.



• **Jacob Setterbo**, Director of Grants, *HIREtech*
Workshop: R&D Tax Credits: A New Non-Dilutive Funding Source for Startups

Dr. Jacob Setterbo is Director of Grants at HIREtech, where he helps life science companies obtain non-dilutive funding. Jacob focuses on small business grants (SBIR/STTRs) from the National Institutes of Health (NIH). He has provided consultation and technical writing for various therapeutic areas across the spectrum of NIH's interests, including pharmaceuticals, medical devices, digital health, and health care delivery. Jacob assists with experimental design and commercialization components of each project. Jacob regularly vets early-stage companies with respect to innovation and commercial potential to determine their applicability for grants. Jacob also assists with R&D Tax Credits at HIREtech. Jacob regularly provides guidance to startups as an advisor for the Texas Medical Center Accelerator (TMCx) in Houston. Jacob also served as a reviewer for the Texas Emerging Technology Fund and as a due diligence team member for the Houston Angel Network. Jacob received his Ph.D. in Biomedical Engineering from University of California, Davis and his B.S. in Civil Engineering from The University of Texas at Austin.



• **Bob Stabell**, Senior Director, *HIREtech*
Workshop: R&D Tax Credits: A New Non-Dilutive Funding Source for Startups

Bob Stabell graduated from Texas A&M University in 1993 with two degrees in Accounting and Finance. Out of college he spent the next five years as a special project accountant for Coopers and Lybrand, before deciding to go on his own as a specialist to regional CPA firms. Later, while employed at NeoDyme Technologies Corporation, he earned his MBA from the University of Texas in their Executive Option program in 2006. Since 2009 he has been with HIREtech as a Senior Director specializing in assisting small businesses to improve their cash flow and tax savings through various programs including the R&D Tax Credit, Section 199, IC DISC, and the Work Opportunity Tax Credit.



• **Teresa Gonzalo**, Business Analyst & Business Development USA, *Venture Valuation*
Workshop: How to Value Your Startup

Teresa is an entrepreneurial scientist specialized in managing and financing business projects from scientific developments. She holds a PhD in Nanomedicine from University of Groningen, the Netherlands, and an MBA in Management of Biotechnology from the IE Business School in Spain. She was CEO and co-founder of Ambiox Biotech (application of dendrimer nanotechnology in cosmetics and agricultural biotechnology). She is co-author of 2 patents in Nanotechnology and Drug Delivery and she was awarded the 2011 MIT TR35 Innovator of the Year award by the Massachusetts Institute of Technology. Teresa was chosen among the top 100 women leaders in Spain in the entrepreneurial and innovative category for two consecutive years in 2012 and 2013. And she was also selected as Woman of the Year by the magazine Scientific Entrepreneurial Woman Today. For her work mentoring startups, IE Business School awarded her the prize for best Mentor of the year. Right now she is in charge of US office for Venture Valuation where she and the global team provide company and product valuations to Life Sciences companies and Healthcare investors facing a fundraising event/licensing deals or M&A.



• **Gary Emmanuel**, Partner, *McDermott Will & Emery, New York*
Workshop: Crowdfunding & REG A+

Gary Emmanuel is a partner in the law firm of McDermott Will & Emery and is based in the Firm's New York office. He focuses his practice on corporate securities matters. With over 15 years of experience, Gary represents both domestic and foreign companies that are navigating the process of capital raising including initial public offerings, registered direct offerings, follow-on offerings, private placements, PIPEs and bridge financings. Gary has worked extensively with biotechnology and other life science companies, both as company counsel and as underwriter's counsel. He advises companies on issues relating to disclosure, periodic reporting, corporate governance, American Depositary Receipt (ADR) programs, and the rules of the NYSE MKT, NYSE and Nasdaq. He also counsels companies in a wide variety of corporate transactions including licensing, reverse mergers, acquisitions and joint ventures. Gary previously served in the Military Court of Appeals of the Israel Defense Forces during his army service and holds the military rank of legal officer. Gary was recognized as a "Rising Star" by Super Lawyers in 2014. Gary received his LL.M. from Benjamin N. Cardozo School of Law. He earned an LL.B., with honors, from Queen Mary, University of London.

• **Eric Orsic**, Partner, *McDermott Will & Emery, Chicago*

Workshop: Crowdfunding & REG A+



Eric Orsic is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm's Chicago office. Eric focuses his practice in the areas of mergers and acquisitions, and securities transactions and compliance. Eric works with both public and privately-held companies to structure and negotiate business acquisitions/dispositions. His public company transactional experience includes public equity and debt offerings, tender offers and going-private transactions. Eric also serves as outside securities counsel to several public companies and advises on SEC compliance matters, including periodic reporting requirements and disclosure issues. In addition, Eric works with both public and private companies in the design and structuring of executive compensation programs, including stock and stock-based compensation plans. Eric is a frequent writer and speaker on corporate and securities law matters. His publications include "Federal Securities Laws Considerations for Equity Compensation Plans," Selected Issues in Equity Compensation, 11th ed., published by the National Center for Employee Ownership.

• **Michael Redman**, CEO, *Oncolix*

Workshop: Tales From the Road



Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006. Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company. His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products. Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is an active member of the Licensing Executives Society and formerly served on its Executive Committee.

• **Rob Hedequist**, President & COO, *Kineta*


Workshop: Tales From the Road



Mr. Hedequist brings over 20 years of product launch and pharmaceutical/ biotechnology industry experience to Kineta. He joined Kineta as SVP Corporate Development in February of 2013. In his role at Kineta and as Chief Development Officer for KPI Therapeutics, he is responsible for devising and executing strategies to meet the company's capital objectives. In the last 2.5 years he and his team have raised over \$33M from private investors, angel groups and Family Offices. Kineta has a unique business model and to date has not sought venture back funding. He has held numerous leadership roles within the commercial sales and marketing organizations of Fortune 100 pharmaceutical and biotechnology companies. Prior to his career in the pharmaceutical industry, Mr. Hedequist had a stellar career in the United States Marine Corps rising from platoon commander to Major and Commanding Officer Fleet Anti-Terrorism Security Company Pacific and is a Desert Shield veteran. A former collegiate athlete, he was a member of the 1979 PAC10 Championship football team and graduated from the University of Southern California with a Bachelor of Science degree in Public Affairs.

• **Larry Cohen**, CEO, *Glycotest*

Workshop: Tales From the Road



Larry Cohen has over 35 year's experience in the In Vitro diagnostic and medical device business. He has led large multinational businesses as well as venture backed start-ups. During his career, he has added value to several enterprises by introducing new products, acquiring businesses and entering new geographical markets. Larry started his career in sales with Beckman Instruments and after a few years was promoted into marketing and introduced the company's first product entry into the automated clinical chemistry market. He was then promoted into general management and re-located to the European headquarters in Geneva, Switzerland. He became the Director of the Europe, Africa and the Middle East which grew significantly during his leadership. He has held senior executive positions at Instrument Laboratory (C.H. Werfen), and Ortho Clinical Diagnostics (J&J), both of which experienced significant growth during his tenure. More recently, he has led smaller organizations to growth and successful liquidity events. He was CEO of HemoSense at its inception, which was ultimately sold to Alere, and he was President of ITC (International Technidyne Corp., a division of Thoratec) which was sold to a Private Equity group.

• **Roger Nolan**, President, *BioKier*


Workshop: Tales From the Road



Roger D. Nolan, Ph.D. is President, Co-Founder, and Chief Operating Officer at BioKier, Inc. Dr. Nolan is experienced in management of preclinical and clinical drug development programs, regulatory strategy and interactions, financing, and outsourcing to specialist service providers. His specific areas of expertise are in diabetes, oncology, and cardiovascular indications. Previous positions held are Senior Director, Science and Technology Evaluation for Calvert Research, Senior Scientist in Clinical Development at Cato Research, and Director Pharmacology at Inmed Pharmaceuticals. At Calvert he directed a drug development program in diabetes that was in-licensed by Sanofi-Aventis. Dr. Nolan started his career at Eastern Virginia Medical School where he had a joint appointment in Biochemistry and Internal Medicine and conducted basic and clinical research at the Strelitz Diabetes Research Center. Dr. Nolan received a PhD in Pharmacology and Biochemistry from Melbourne University; and completed Postdoctorate fellowships at the National Institute of Environmental Health Sciences and at Burroughs Wellcome.

• **Jonathan Cohen**, President & CEO, *20/20 GeneSystems*

Workshop: Tales From the Road



Mr. Cohen is the founding CEO of 20/20 GeneSystems. In that capacity he has lead the company to raise over \$10 million in equity investments, procure over \$7 million in funding from government and corporate sources, and forge license and distribution agreements with several Fortune 500 companies. He also spearheaded the launch of 20/20's highly successful BioCheck product which is used by over 500 emergency response organizations worldwide. Active in public policy initiatives on behalf of the biotechnology industry, Mr. Cohen conceived of and helped bring about the passage of the Maryland Biotechnology Investment Tax Credit which is widely deemed to be the most effective investment incentive in the U.S. Cohen is a founding director of the Small Biotechnology Business Coalition. Before starting 20/20 Mr. Cohen was patent and general counsel for two publicly traded companies: Ventana Medical Systems Inc. (acquired by Roche diagnostics, 2008) and Oncor Inc. Mr. Cohen is a registered patent attorney with over 18 years' experience in biotechnology patents and licensing matters. Cohen has a Master of Science Degree in Biotechnology from Johns Hopkins University and a law degree from the American University.

• **Colin Widen**, CEO, *Boston Innovation Capital*

Workshop: Boston Innovation Capital



Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the firm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.

• **Dennis Ford**, Founder & CEO, *Life Science Naiton*

Workshop: Branding & Messaging




Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career launching new companies. Over the last decade, he has worked extensively with global alternative investors interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. Before LSN, Dennis was the President and CEO of Brighton House Associates (BHA). BHA was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors. Ford is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto*. Ford teaches Entrepreneurship Sales & Marketing to undergraduate and graduate students at the University of Massachusetts Boston.




ACTIVE EARLY STAGE INVESTORS
ACROSS 10 CATEGORIES

RESI@TMCx 2016 Investor Breakdown



DYNAMIC PARTNERING FORUM
BASED ON FIT

Who Meets with Whom at RESI@TMCx



As of March 30, 2016

RESI provides a partnering forum for all stakeholders in the early stage life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.





SPONSORS



Title Sponsors



Gold Sponsor



Silver Sponsors



Bronze Sponsor



SPONSORS



JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.



Housed in 100,000 sq. ft. of a former Nabisco cookie factory, Texas Medical Center accelerator (TMCx) is a 6 month program that provides life science and digital health entrepreneurs with a collaborative ecosystem to accelerate their path to market. TMCx resources for startups include: an all-star network of advisors, a newly renovated office space, and unprecedented connections to the world's largest medical center. From ideation to commercialization, we work closely with life science and digital health startups to transform scientific innovations into tangible tools that save lives, manage disease, and improve quality of life.



Life Science Nation (LSN) accelerates fundraising using its matching platform to create highly compatible relationships between early stage scientists/ entrepreneurs and emerging technology investors. LSN researches and curates market intelligence on two industry sectors. The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors.



McDermott Will & Emery is a premier international law firm with a diversified business practice. Established in 1934 as a tax practice in Chicago, Illinois, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. McDermott has 80 years of serving a broad range of client interests. Our Life Sciences Industry Group is composed of 135 professionals, 60 with advanced science degrees and many others with government and industry experience, working across 19 offices around the world. With insights drawn from the only health practice ranked Tier 1 nationally by Chambers USA and our global reach, we deliver integrated business solutions to our clients, bringing the required experience from our leading tax, health, intellectual property, antitrust and regulatory practices to solve our client's challenges.



HIREtech, is a technology focused human capital management solution and tax incentive firm helping companies capturing valuable tax credits. Exclusive technology enables companies to access real time data needed to make important decisions. HIREtech's solutions include hiring tax incentives, research and development tax incentive and other specialized tax incentive programs for companies of all sizes including startups. Bridging the gap between human resources and financial executives, HIREtech delivers innovation technology and award winning customer service.



WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to help its global partners in shortening the cycle and lowering the cost of R&D. WuXi is also building a platform to provide clinical diagnostic and genomic services directly to physicians and their patients globally.



Created in 1979 by the healthcare technology industry, Medmarc's purpose is to be the superior provider of liability insurance and related risk management solutions and to support the development, testing and delivery of products that save lives and improve the quality of life. Through our strategic alliances with The Hartford and clinical trial industry experts, we offer tailored insurance protection specifically designed for the broad spectrum of needs of the medical technology and life sciences industry. From ideas and prototypes to the reality of commercialization and success – We can Meet Your Changing Needs.

Media Partners





RESI

REDEFINING
EARLY STAGE
INVESTMENTS

CONFERENCE SERIES

The **RESI Conference Series** offers fundraising CEOs an opportunity to meet early stage investors that are a fit for their sector four times every year. Use the discount code **RESISERIES** for **\$100** off of your RESI conference series registration.



HOUSTON, TX

APRIL 11, 2016



TORONTO, ON

JUNE 23, 2016



BOSTON, MA

SEPTEMBER 13, 2016



SAN FRANCISCO, CA

JANUARY 10, 2017

